CHICAGO – The list of off-label uses for biologic agents is growing, according to Dr. Eric Ruderman, who provided an update on dermatologic, ophthalmologic, and other uses at a symposium sponsored by the American College of Rheumatology.

There are scant data to support off-label uses, and these typically come from retrospective reports, small case series, or anecdotal experience, with a few exceptions, said Dr. Ruderman, a rheumatologist at Northwestern University, Chicago.

Dermatologic Uses

Infliximab is increasingly being used to treat hidradenitis suppurativa and neutrophilic dermatoses despite a lack of data from randomized controlled trials to support this practice. Findings from a small double-blind crossover trial involving 38 patients who were treated for 8 weeks, however, did suggest that infliximab improves pain, disease severity, and quality of life.

Some benefit was also shown with adalimumab in this disease in a recent case series, while benefits with etanercept were less clear in two open-label trials. Patients in the etanercept trials also had worsening of their condition after etanercept was discontinued.

As for neutrophilic dermatoses, infliximab appears to be useful for pyoderma gangrenosum and possibly for Sweet’s syndrome. In a double-blind study of 30 patients with pyoderma gangrenosum, a single dose of 5 mg/kg was associated with a 46% improvement, compared with 6% for placebo. Furthermore, nonresponders on placebo at 2 weeks were treated with infliximab with a 60% response rate, and 21% of treated patients achieved remission.

Case reports also show a benefit of infliximab in patients with Sweet's syndrome, but no controlled data are available for this condition, Dr. Ruderman said.

Ophthalmologic Uses

Biologic therapies being used for ophthalmologic conditions include infliximab, adalimumab, and/or daclizumab for childhood uveitis and other types of uveitis, he noted.

Retrospective case series have shown benefit with infliximab, adalimumab, and daclizumab in childhood uveitis, and an open-label prospective study comparing adalimumab with infliximab demonstrated greater benefit with adalimumab (60% vs. 20% remission at 40 months), he said.

Infliximab also may have some benefit in ocular sarcoidosis, with case reports and small open-label series demonstrating some benefit. Etanercept in this disease, however, appears to be no more effective than placebo, based on findings of a randomized study of 18 patients treated for 6 months.

In Behçet's uveitis, case reports and findings from two small open trials suggest some benefit with infliximab. In the open trials, 9 of 12 patients responded to a dose of 5 mg/kg, Dr. Ruderman said, adding that treatment helped reduce steroid use, but relapse was frequent after treatment discontinuation, suggesting that ongoing therapy is necessary.

Pulmonary Uses

Other conditions in which biologics are currently being used include pulmonary and extrapulmonary sarcoidosis, asthma, and chronic obstructive pulmonary disease (COPD).

In one "nicely done" randomized, controlled, multicenter study of 138 pulmonary sarcoidosis patients, infliximab was superior to placebo for improving the percent predicted forced vital capacity at 24 weeks, and also led to improvement in extrapulmonary disease, Dr. Ruderman said.

Improvements in scores on the extrapulmonary physician organ severity tool (ePOST) were better in the treatment versus placebo group at 24 weeks, even after adjusting for the number of organs involved, he said.

Findings from an open-label study of etanercept in this disease, however, showed that only 5 of 17 patients had "success," which was defined as lack of deterioration on x-rays or pulmonary function tests.

Case reports and retrospective data – but not randomized controlled data – have also shown some benefit of infliximab for cutaneous sarcoidosis. In 54 patients who received 116 courses of therapy, resolution or near resolution of lupus pernio was achieved in 77% of patients versus 11%-29% of those treated with steroids and other therapy. Some case reports show benefit in neurosarcoidosis, as well, but no solid data are available to back those up, Dr. Ruderman said.

For asthma, there may be a role for tumor necrosis factor inhibitors, although one randomized controlled trial showed no benefit with golimumab.

The Brigham RA Sequential Study, for example, demonstrated improvement with TNF inhibitors in nine patients with both rheumatoid arthritis (RA) and asthma, and findings from a small, controlled trial of etanercept showed some benefit on several measures of response. The benefits in that study, however, were not clear-cut, and two other etanercept trials, as well as one infliximab trial, failed to show any benefit in asthma.

Similarly, golimumab showed no benefit in a 52-week randomized, controlled trial of 231 patients with severe uncontrolled asthma. Patients in that trial had no improvements over placebo in forced expiratory volume in 1 second (FEV₁) or exacerbations, and they experienced frequent severe infections, Dr. Ruderman said.

Two studies found that infliximab therapy provided no benefit in the management of COPD. The first was a 24-week study of 3 mg/kg, 5 mg/kg, and placebo in 159 patients. The findings showed no improvement in health status or FEV₁, no lessening of exacerbations with treatment vs. placebo, and an increase in the risk of pneumonia in the treated group. The second study was an observational study involving a cohort of 15,771 patients with both RA and COPD. In this study, however, treatment with etanercept was associated with a 50% reduction in the rate of COPD hospitalization.

"I don’t know entirely what to make of that," Dr. Ruderman said, adding that it might be a result of improvement in the RA and thus overall health.

It's an interesting observation, but overall the findings don't say much about the off-label use of TNF inhibitors in COPD, he said.

Dr. Ruderman reported receiving consulting fees and/or research grants from Abbott, Allos, Amgen, Biogenidec, Celgene, Centocor, Crescendo, CVS/Caremark, Pfizer, and UCB.

CHICAGO – The list of off-label uses for biologic agents is growing, according to Dr. Eric Ruderman, who provided an update on dermatologic, ophthalmologic, and other uses at a symposium sponsored by the American College of Rheumatology.

There are scant data to support off-label uses, and these typically come from retrospective reports, small case series, or anecdotal experience, with a few exceptions, said Dr. Ruderman, a rheumatologist at Northwestern University, Chicago.

Dermatologic Uses

Infliximab is increasingly being used to treat hidradenitis suppurativa and neutrophilic dermatoses despite a lack of data from randomized controlled trials to support this practice. Findings from a small double-blind crossover trial involving 38 patients who were treated for 8 weeks, however, did suggest that infliximab improves pain, disease severity, and quality of life.

Some benefit was also shown with adalimumab in this disease in a recent case series, while benefits with etanercept were less clear in two open-label trials. Patients in the etanercept trials also had worsening of their condition after etanercept was discontinued.

As for neutrophilic dermatoses, infliximab appears to be useful for pyoderma gangrenosum and possibly for Sweet’s syndrome. In a double-blind study of 30 patients with pyoderma gangrenosum, a single dose of 5 mg/kg was associated with a 46% improvement, compared with 6% for placebo. Furthermore, nonresponders on placebo at 2 weeks were treated with infliximab with a 60% response rate, and 21% of treated patients achieved remission.

Case reports also show a benefit of infliximab in patients with Sweet's syndrome, but no controlled data are available for this condition, Dr. Ruderman said.

Ophthalmologic Uses

Biologic therapies being used for ophthalmologic conditions include infliximab, adalimumab, and/or daclizumab for childhood uveitis and other types of uveitis, he noted.

Retrospective case series have shown benefit with infliximab, adalimumab, and daclizumab in childhood uveitis, and an open-label prospective study comparing adalimumab with infliximab demonstrated greater benefit with adalimumab (60% vs. 20% remission at 40 months), he said.

Infliximab also may have some benefit in ocular sarcoidosis, with case reports and small open-label series demonstrating some benefit. Etanercept in this disease, however, appears to be no more effective than placebo, based on findings of a randomized study of 18 patients treated for 6 months.

In Behçet's uveitis, case reports and findings from two small open trials suggest some benefit with infliximab. In the open trials, 9 of 12 patients responded to a dose of 5 mg/kg, Dr. Ruderman said, adding that treatment helped reduce steroid use, but relapse was frequent after treatment discontinuation, suggesting that ongoing therapy is necessary.

Pulmonary Uses

Other conditions in which biologics are currently being used include pulmonary and extrapulmonary sarcoidosis, asthma, and chronic obstructive pulmonary disease (COPD).

In one "nicely done" randomized, controlled, multicenter study of 138 pulmonary sarcoidosis patients, infliximab was superior to placebo for improving the percent predicted forced vital capacity at 24 weeks, and also led to improvement in extrapulmonary disease, Dr. Ruderman said.

Improvements in scores on the extrapulmonary physician organ severity tool (ePOST) were better in the treatment versus placebo group at 24 weeks, even after adjusting for the number of organs involved, he said.

Findings from an open-label study of etanercept in this disease, however, showed that only 5 of 17 patients had "success," which was defined as lack of deterioration on x-rays or pulmonary function tests.

Case reports and retrospective data – but not randomized controlled data – have also shown some benefit of infliximab for cutaneous sarcoidosis. In 54 patients who received 116 courses of therapy, resolution or near resolution of lupus pernio was achieved in 77% of patients versus 11%-29% of those treated with steroids and other therapy. Some case reports show benefit in neurosarcoidosis, as well, but no solid data are available to back those up, Dr. Ruderman said.

For asthma, there may be a role for tumor necrosis factor inhibitors, although one randomized controlled trial showed no benefit with golimumab.

The Brigham RA Sequential Study, for example, demonstrated improvement with TNF inhibitors in nine patients with both rheumatoid arthritis (RA) and asthma, and findings from a small, controlled trial of etanercept showed some benefit on several measures of response. The benefits in that study, however, were not clear-cut, and two other etanercept trials, as well as one infliximab trial, failed to show any benefit in asthma.

Similarly, golimumab showed no benefit in a 52-week randomized, controlled trial of 231 patients with severe uncontrolled asthma. Patients in that trial had no improvements over placebo in forced expiratory volume in 1 second (FEV₁) or exacerbations, and they experienced frequent severe infections, Dr. Ruderman said.

Two studies found that infliximab therapy provided no benefit in the management of COPD. The first was a 24-week study of 3 mg/kg, 5 mg/kg, and placebo in 159 patients. The findings showed no improvement in health status or FEV₁, no lessening of exacerbations with treatment vs. placebo, and an increase in the risk of pneumonia in the treated group. The second study was an observational study involving a cohort of 15,771 patients with both RA and COPD. In this study, however, treatment with etanercept was associated with a 50% reduction in the rate of COPD hospitalization.

"I don’t know entirely what to make of that," Dr. Ruderman said, adding that it might be a result of improvement in the RA and thus overall health.

It's an interesting observation, but overall the findings don't say much about the off-label use of TNF inhibitors in COPD, he said.

Dr. Ruderman reported receiving consulting fees and/or research grants from Abbott, Allos, Amgen, Biogenidec, Celgene, Centocor, Crescendo, CVS/Caremark, Pfizer, and UCB.

CHICAGO – The list of off-label uses for biologic agents is growing, according to Dr. Eric Ruderman, who provided an update on dermatologic, ophthalmologic, and other uses at a symposium sponsored by the American College of Rheumatology.

There are scant data to support off-label uses, and these typically come from retrospective reports, small case series, or anecdotal experience, with a few exceptions, said Dr. Ruderman, a rheumatologist at Northwestern University, Chicago.

Dermatologic Uses

Infliximab is increasingly being used to treat hidradenitis suppurativa and neutrophilic dermatoses despite a lack of data from randomized controlled trials to support this practice. Findings from a small double-blind crossover trial involving 38 patients who were treated for 8 weeks, however, did suggest that infliximab improves pain, disease severity, and quality of life.

Some benefit was also shown with adalimumab in this disease in a recent case series, while benefits with etanercept were less clear in two open-label trials. Patients in the etanercept trials also had worsening of their condition after etanercept was discontinued.

As for neutrophilic dermatoses, infliximab appears to be useful for pyoderma gangrenosum and possibly for Sweet’s syndrome. In a double-blind study of 30 patients with pyoderma gangrenosum, a single dose of 5 mg/kg was associated with a 46% improvement, compared with 6% for placebo. Furthermore, nonresponders on placebo at 2 weeks were treated with infliximab with a 60% response rate, and 21% of treated patients achieved remission.

Case reports also show a benefit of infliximab in patients with Sweet's syndrome, but no controlled data are available for this condition, Dr. Ruderman said.

Ophthalmologic Uses

Biologic therapies being used for ophthalmologic conditions include infliximab, adalimumab, and/or daclizumab for childhood uveitis and other types of uveitis, he noted.

Retrospective case series have shown benefit with infliximab, adalimumab, and daclizumab in childhood uveitis, and an open-label prospective study comparing adalimumab with infliximab demonstrated greater benefit with adalimumab (60% vs. 20% remission at 40 months), he said.

Infliximab also may have some benefit in ocular sarcoidosis, with case reports and small open-label series demonstrating some benefit. Etanercept in this disease, however, appears to be no more effective than placebo, based on findings of a randomized study of 18 patients treated for 6 months.

In Behçet's uveitis, case reports and findings from two small open trials suggest some benefit with infliximab. In the open trials, 9 of 12 patients responded to a dose of 5 mg/kg, Dr. Ruderman said, adding that treatment helped reduce steroid use, but relapse was frequent after treatment discontinuation, suggesting that ongoing therapy is necessary.

Pulmonary Uses

Other conditions in which biologics are currently being used include pulmonary and extrapulmonary sarcoidosis, asthma, and chronic obstructive pulmonary disease (COPD).

In one "nicely done" randomized, controlled, multicenter study of 138 pulmonary sarcoidosis patients, infliximab was superior to placebo for improving the percent predicted forced vital capacity at 24 weeks, and also led to improvement in extrapulmonary disease, Dr. Ruderman said.

Improvements in scores on the extrapulmonary physician organ severity tool (ePOST) were better in the treatment versus placebo group at 24 weeks, even after adjusting for the number of organs involved, he said.

Findings from an open-label study of etanercept in this disease, however, showed that only 5 of 17 patients had "success," which was defined as lack of deterioration on x-rays or pulmonary function tests.

Case reports and retrospective data – but not randomized controlled data – have also shown some benefit of infliximab for cutaneous sarcoidosis. In 54 patients who received 116 courses of therapy, resolution or near resolution of lupus pernio was achieved in 77% of patients versus 11%-29% of those treated with steroids and other therapy. Some case reports show benefit in neurosarcoidosis, as well, but no solid data are available to back those up, Dr. Ruderman said.

For asthma, there may be a role for tumor necrosis factor inhibitors, although one randomized controlled trial showed no benefit with golimumab.

The Brigham RA Sequential Study, for example, demonstrated improvement with TNF inhibitors in nine patients with both rheumatoid arthritis (RA) and asthma, and findings from a small, controlled trial of etanercept showed some benefit on several measures of response. The benefits in that study, however, were not clear-cut, and two other etanercept trials, as well as one infliximab trial, failed to show any benefit in asthma.

Similarly, golimumab showed no benefit in a 52-week randomized, controlled trial of 231 patients with severe uncontrolled asthma. Patients in that trial had no improvements over placebo in forced expiratory volume in 1 second (FEV₁) or exacerbations, and they experienced frequent severe infections, Dr. Ruderman said.

Two studies found that infliximab therapy provided no benefit in the management of COPD. The first was a 24-week study of 3 mg/kg, 5 mg/kg, and placebo in 159 patients. The findings showed no improvement in health status or FEV₁, no lessening of exacerbations with treatment vs. placebo, and an increase in the risk of pneumonia in the treated group. The second study was an observational study involving a cohort of 15,771 patients with both RA and COPD. In this study, however, treatment with etanercept was associated with a 50% reduction in the rate of COPD hospitalization.

"I don’t know entirely what to make of that," Dr. Ruderman said, adding that it might be a result of improvement in the RA and thus overall health.

It's an interesting observation, but overall the findings don't say much about the off-label use of TNF inhibitors in COPD, he said.

Dr. Ruderman reported receiving consulting fees and/or research grants from Abbott, Allos, Amgen, Biogenidec, Celgene, Centocor, Crescendo, CVS/Caremark, Pfizer, and UCB.

CHICAGO (EGMN) – The list of off-label uses for biologic agents is growing, and rheumatologists should stay abreast of even the nonrheumatologic uses, according to Dr. Eric Ruderman, who provided an update on dermatologic, ophthalmologic, and other uses at a symposium sponsored by the American College of Rheumatology.

"My goal is to give you some guidance when somebody asks, because what you’re going to find is that the dermatologists, ophthalmologists, and others are going to ask you as the rheumatologist, who is supposedly the expert in biologic therapy, what is the role for this, that, or the other drug," said Dr. Ruderman, a rheumatologist at Northwestern University, Chicago.

There are scant data to support off-label uses, and these typically come from retrospective reports, small case series, or anecdotal experience, with a few exceptions, he said.

In dermatology, for example, infliximab is increasingly being used to treat hidradenitis suppurativa and neutrophilic dermatoses despite a lack of data from randomized controlled trials to support this practice. Findings from a small double-blind crossover trial involving 38 patients who were treated for 8 weeks, however, did suggest that infliximab improves pain, disease severity, and quality of life.

Some benefit was also shown with adalimumab in this disease in a recent case series, while benefits with etanercept were less clear in two open-label trials. Patients in the etanercept trials also had worsening of their condition after etanercept was discontinued.

As for neutrophilic dermatoses, infliximab appears to be useful for pyoderma gangrenosum and possibly for Sweet’s syndrome. In a double-blind study of 30 patients with pyoderma gangrenosum, a single dose of 5 mg/kg was associated with a 46% improvement, compared with 6% for placebo. Furthermore, nonresponders on placebo at 2 weeks were treated with infliximab with a 60% response rate, and 21% of treated patients achieved remission.

Case reports also show a benefit of infliximab in patients with Sweet’s syndrome, but no controlled data are available for this condition, Dr. Ruderman said.

Biologic therapies being used for ophthalmologic conditions include infliximab, adalimumab, and/or daclizumab for childhood uveitis and other types of uveitis, he noted.

Retrospective case series have shown benefit with infliximab, adalimumab, and daclizumab in childhood uveitis, and an open-label prospective study comparing adalimumab with infliximab demonstrated greater benefit with adalimumab (60% vs. 20% remission at 40 months), he said.

Infliximab also may have some benefit in ocular sarcoidosis, with case reports and small open-label series demonstrating some benefit. Etanercept in this disease, however, appears to be no more effective than placebo, based on findings of a randomized study of 18 patients treated for 6 months.

In Behçet’s uveitis, case reports and findings from two small open trials suggest some benefit with infliximab. In the open trials, 9 of 12 patients responded to a dose of 5 mg/kg, Dr. Ruderman said, adding that treatment helped reduce steroid use, but relapse was frequent after treatment discontinuation, suggesting that ongoing therapy is necessary.

Other conditions in which biologics are currently being used include pulmonary and extrapulmonary sarcoidosis, asthma, and chronic obstructive pulmonary disease (COPD).

In one "nicely done" randomized, controlled, multicenter study of 138 pulmonary sarcoidosis patients, infliximab was superior to placebo for improving the percent predicted forced vital capacity at 24 weeks, and also led to improvement in extrapulmonary disease, Dr. Ruderman said.

Improvements in scores on the extrapulmonary physician organ severity tool (ePOST) were better in the treatment versus placebo group at 24 weeks, even after adjusting for the number of organs involved, he said.

Findings from an open-label study of etanercept in this disease, however, showed that only 5 of 17 patients had "success," which was defined as lack of deterioration on x-rays or pulmonary function tests.

Case reports and retrospective data – but not randomized controlled data – have also shown some benefit of infliximab for cutaneous sarcoidosis. In 54 patients who received 116 courses of therapy, resolution or near resolution of lupus pernio was achieved in 77% of patients versus 11%-29% of those treated with steroids and other therapy. Some case reports show benefit in neurosarcoidosis, as well, but no solid data are available to back those up, Dr. Ruderman said.

For asthma, there may be a role for tumor necrosis factor inhibitors, although one randomized controlled trial showed no benefit with golimumab.

The Brigham RA Sequential Study, for example, demonstrated improvement with TNF inhibitors in nine patients with both rheumatoid arthritis (RA) and asthma, and findings from a small, controlled trial of etanercept showed some benefit on several measures of response. The benefits in that study, however, were not clear-cut, and two other etanercept trials, as well as one infliximab trial, failed to show any benefit in asthma.

Similarly, golimumab showed no benefit in a 52-week randomized, controlled trial of 231 patients with severe uncontrolled asthma. Patients in that trial had no improvements over placebo in forced expiratory volume in 1 second (FEV₁) or exacerbations, and they experienced frequent severe infections, Dr. Ruderman said.

Two studies found that infliximab therapy provided no benefit in the management of COPD. The first was a 24-week study of 3 mg/kg, 5 mg/kg, and placebo in 159 patients. The findings showed no improvement in health status or FEV₁, no lessening of exacerbations with treatment vs. placebo, and an increase in the risk of pneumonia in the treated group. The second study was an observational study involving a cohort of 15,771 patients with both RA and COPD. In this study, however, treatment with etanercept was associated with a 50% reduction in the rate of COPD hospitalization.

"I don’t know entirely what to make of that," Dr. Ruderman said, adding that it might be a result of improvement in the RA and thus overall health.

It’s an interesting observation, but overall the findings don’t say much about the off-label use of TNF inhibitors in COPD, he said.

Dr. Ruderman reported receiving consulting fees and/or research grants from Abbott, Allos, Amgen, Biogenidec, Celgene, Centocor, Crescendo, CVS/Caremark, Pfizer, and UCB.

CHICAGO (EGMN) – The list of off-label uses for biologic agents is growing, and rheumatologists should stay abreast of even the nonrheumatologic uses, according to Dr. Eric Ruderman, who provided an update on dermatologic, ophthalmologic, and other uses at a symposium sponsored by the American College of Rheumatology.

"My goal is to give you some guidance when somebody asks, because what you’re going to find is that the dermatologists, ophthalmologists, and others are going to ask you as the rheumatologist, who is supposedly the expert in biologic therapy, what is the role for this, that, or the other drug," said Dr. Ruderman, a rheumatologist at Northwestern University, Chicago.

There are scant data to support off-label uses, and these typically come from retrospective reports, small case series, or anecdotal experience, with a few exceptions, he said.

In dermatology, for example, infliximab is increasingly being used to treat hidradenitis suppurativa and neutrophilic dermatoses despite a lack of data from randomized controlled trials to support this practice. Findings from a small double-blind crossover trial involving 38 patients who were treated for 8 weeks, however, did suggest that infliximab improves pain, disease severity, and quality of life.

Some benefit was also shown with adalimumab in this disease in a recent case series, while benefits with etanercept were less clear in two open-label trials. Patients in the etanercept trials also had worsening of their condition after etanercept was discontinued.

As for neutrophilic dermatoses, infliximab appears to be useful for pyoderma gangrenosum and possibly for Sweet’s syndrome. In a double-blind study of 30 patients with pyoderma gangrenosum, a single dose of 5 mg/kg was associated with a 46% improvement, compared with 6% for placebo. Furthermore, nonresponders on placebo at 2 weeks were treated with infliximab with a 60% response rate, and 21% of treated patients achieved remission.

Case reports also show a benefit of infliximab in patients with Sweet’s syndrome, but no controlled data are available for this condition, Dr. Ruderman said.

Biologic therapies being used for ophthalmologic conditions include infliximab, adalimumab, and/or daclizumab for childhood uveitis and other types of uveitis, he noted.

Retrospective case series have shown benefit with infliximab, adalimumab, and daclizumab in childhood uveitis, and an open-label prospective study comparing adalimumab with infliximab demonstrated greater benefit with adalimumab (60% vs. 20% remission at 40 months), he said.

Infliximab also may have some benefit in ocular sarcoidosis, with case reports and small open-label series demonstrating some benefit. Etanercept in this disease, however, appears to be no more effective than placebo, based on findings of a randomized study of 18 patients treated for 6 months.

In Behçet’s uveitis, case reports and findings from two small open trials suggest some benefit with infliximab. In the open trials, 9 of 12 patients responded to a dose of 5 mg/kg, Dr. Ruderman said, adding that treatment helped reduce steroid use, but relapse was frequent after treatment discontinuation, suggesting that ongoing therapy is necessary.

Other conditions in which biologics are currently being used include pulmonary and extrapulmonary sarcoidosis, asthma, and chronic obstructive pulmonary disease (COPD).

In one "nicely done" randomized, controlled, multicenter study of 138 pulmonary sarcoidosis patients, infliximab was superior to placebo for improving the percent predicted forced vital capacity at 24 weeks, and also led to improvement in extrapulmonary disease, Dr. Ruderman said.

Improvements in scores on the extrapulmonary physician organ severity tool (ePOST) were better in the treatment versus placebo group at 24 weeks, even after adjusting for the number of organs involved, he said.

Findings from an open-label study of etanercept in this disease, however, showed that only 5 of 17 patients had "success," which was defined as lack of deterioration on x-rays or pulmonary function tests.

Case reports and retrospective data – but not randomized controlled data – have also shown some benefit of infliximab for cutaneous sarcoidosis. In 54 patients who received 116 courses of therapy, resolution or near resolution of lupus pernio was achieved in 77% of patients versus 11%-29% of those treated with steroids and other therapy. Some case reports show benefit in neurosarcoidosis, as well, but no solid data are available to back those up, Dr. Ruderman said.

For asthma, there may be a role for tumor necrosis factor inhibitors, although one randomized controlled trial showed no benefit with golimumab.

The Brigham RA Sequential Study, for example, demonstrated improvement with TNF inhibitors in nine patients with both rheumatoid arthritis (RA) and asthma, and findings from a small, controlled trial of etanercept showed some benefit on several measures of response. The benefits in that study, however, were not clear-cut, and two other etanercept trials, as well as one infliximab trial, failed to show any benefit in asthma.

Similarly, golimumab showed no benefit in a 52-week randomized, controlled trial of 231 patients with severe uncontrolled asthma. Patients in that trial had no improvements over placebo in forced expiratory volume in 1 second (FEV₁) or exacerbations, and they experienced frequent severe infections, Dr. Ruderman said.

Two studies found that infliximab therapy provided no benefit in the management of COPD. The first was a 24-week study of 3 mg/kg, 5 mg/kg, and placebo in 159 patients. The findings showed no improvement in health status or FEV₁, no lessening of exacerbations with treatment vs. placebo, and an increase in the risk of pneumonia in the treated group. The second study was an observational study involving a cohort of 15,771 patients with both RA and COPD. In this study, however, treatment with etanercept was associated with a 50% reduction in the rate of COPD hospitalization.

"I don’t know entirely what to make of that," Dr. Ruderman said, adding that it might be a result of improvement in the RA and thus overall health.

It’s an interesting observation, but overall the findings don’t say much about the off-label use of TNF inhibitors in COPD, he said.

Dr. Ruderman reported receiving consulting fees and/or research grants from Abbott, Allos, Amgen, Biogenidec, Celgene, Centocor, Crescendo, CVS/Caremark, Pfizer, and UCB.

CHICAGO (EGMN) – The list of off-label uses for biologic agents is growing, and rheumatologists should stay abreast of even the nonrheumatologic uses, according to Dr. Eric Ruderman, who provided an update on dermatologic, ophthalmologic, and other uses at a symposium sponsored by the American College of Rheumatology.

"My goal is to give you some guidance when somebody asks, because what you’re going to find is that the dermatologists, ophthalmologists, and others are going to ask you as the rheumatologist, who is supposedly the expert in biologic therapy, what is the role for this, that, or the other drug," said Dr. Ruderman, a rheumatologist at Northwestern University, Chicago.

There are scant data to support off-label uses, and these typically come from retrospective reports, small case series, or anecdotal experience, with a few exceptions, he said.

In dermatology, for example, infliximab is increasingly being used to treat hidradenitis suppurativa and neutrophilic dermatoses despite a lack of data from randomized controlled trials to support this practice. Findings from a small double-blind crossover trial involving 38 patients who were treated for 8 weeks, however, did suggest that infliximab improves pain, disease severity, and quality of life.

Some benefit was also shown with adalimumab in this disease in a recent case series, while benefits with etanercept were less clear in two open-label trials. Patients in the etanercept trials also had worsening of their condition after etanercept was discontinued.

As for neutrophilic dermatoses, infliximab appears to be useful for pyoderma gangrenosum and possibly for Sweet’s syndrome. In a double-blind study of 30 patients with pyoderma gangrenosum, a single dose of 5 mg/kg was associated with a 46% improvement, compared with 6% for placebo. Furthermore, nonresponders on placebo at 2 weeks were treated with infliximab with a 60% response rate, and 21% of treated patients achieved remission.

Case reports also show a benefit of infliximab in patients with Sweet’s syndrome, but no controlled data are available for this condition, Dr. Ruderman said.

Biologic therapies being used for ophthalmologic conditions include infliximab, adalimumab, and/or daclizumab for childhood uveitis and other types of uveitis, he noted.

Retrospective case series have shown benefit with infliximab, adalimumab, and daclizumab in childhood uveitis, and an open-label prospective study comparing adalimumab with infliximab demonstrated greater benefit with adalimumab (60% vs. 20% remission at 40 months), he said.

Infliximab also may have some benefit in ocular sarcoidosis, with case reports and small open-label series demonstrating some benefit. Etanercept in this disease, however, appears to be no more effective than placebo, based on findings of a randomized study of 18 patients treated for 6 months.

In Behçet’s uveitis, case reports and findings from two small open trials suggest some benefit with infliximab. In the open trials, 9 of 12 patients responded to a dose of 5 mg/kg, Dr. Ruderman said, adding that treatment helped reduce steroid use, but relapse was frequent after treatment discontinuation, suggesting that ongoing therapy is necessary.

Other conditions in which biologics are currently being used include pulmonary and extrapulmonary sarcoidosis, asthma, and chronic obstructive pulmonary disease (COPD).

In one "nicely done" randomized, controlled, multicenter study of 138 pulmonary sarcoidosis patients, infliximab was superior to placebo for improving the percent predicted forced vital capacity at 24 weeks, and also led to improvement in extrapulmonary disease, Dr. Ruderman said.

Improvements in scores on the extrapulmonary physician organ severity tool (ePOST) were better in the treatment versus placebo group at 24 weeks, even after adjusting for the number of organs involved, he said.

Findings from an open-label study of etanercept in this disease, however, showed that only 5 of 17 patients had "success," which was defined as lack of deterioration on x-rays or pulmonary function tests.

Case reports and retrospective data – but not randomized controlled data – have also shown some benefit of infliximab for cutaneous sarcoidosis. In 54 patients who received 116 courses of therapy, resolution or near resolution of lupus pernio was achieved in 77% of patients versus 11%-29% of those treated with steroids and other therapy. Some case reports show benefit in neurosarcoidosis, as well, but no solid data are available to back those up, Dr. Ruderman said.

For asthma, there may be a role for tumor necrosis factor inhibitors, although one randomized controlled trial showed no benefit with golimumab.

The Brigham RA Sequential Study, for example, demonstrated improvement with TNF inhibitors in nine patients with both rheumatoid arthritis (RA) and asthma, and findings from a small, controlled trial of etanercept showed some benefit on several measures of response. The benefits in that study, however, were not clear-cut, and two other etanercept trials, as well as one infliximab trial, failed to show any benefit in asthma.

Similarly, golimumab showed no benefit in a 52-week randomized, controlled trial of 231 patients with severe uncontrolled asthma. Patients in that trial had no improvements over placebo in forced expiratory volume in 1 second (FEV₁) or exacerbations, and they experienced frequent severe infections, Dr. Ruderman said.

Two studies found that infliximab therapy provided no benefit in the management of COPD. The first was a 24-week study of 3 mg/kg, 5 mg/kg, and placebo in 159 patients. The findings showed no improvement in health status or FEV₁, no lessening of exacerbations with treatment vs. placebo, and an increase in the risk of pneumonia in the treated group. The second study was an observational study involving a cohort of 15,771 patients with both RA and COPD. In this study, however, treatment with etanercept was associated with a 50% reduction in the rate of COPD hospitalization.

"I don’t know entirely what to make of that," Dr. Ruderman said, adding that it might be a result of improvement in the RA and thus overall health.

It’s an interesting observation, but overall the findings don’t say much about the off-label use of TNF inhibitors in COPD, he said.

Dr. Ruderman reported receiving consulting fees and/or research grants from Abbott, Allos, Amgen, Biogenidec, Celgene, Centocor, Crescendo, CVS/Caremark, Pfizer, and UCB.

CHICAGO – Glucocorticoids remain the cornerstone of therapy for giant cell arteritis, but aspirin and methotrexate can be useful as adjunctive therapies.

Infliximab, however, does not appear to be of benefit in this disease, said Dr. Philip Seo at a symposium sponsored by the American College of Rheumatology.

The benefits of aspirin were demonstrated in a 2004 retrospective study of 175 patients with giant cell arteritis (GCA), including 36 who were being treated with 100 mg/day of aspirin from the time of diagnosis and 139 who were not (Arthritis Rheum. 2004;50:1332-7). Aspirin was shown to be associated with a reduced risk of cranial ischemic events, including acute vision loss and cerebrovascular accident, said Dr. Seo, codirector of the vasculitis center at the Johns Hopkins University, Baltimore.

In that study, only 8% of patients who were treated with aspirin, compared with 29% of those not treated with aspirin, experienced a cranial ischemic event, and that was despite the fact that cerebrovascular risk factors were present in 38.9% and 20% of patients, respectively. In 166 patients from the study who were followed for at least 3 months, the findings were similar: In all, 2.7% of 73 patients treated with aspirin, compared with 12.9% of those not treated with aspirin, experienced a cerebral ischemic event during follow-up, despite 28.8% and 12.9% in the groups, respectively, having cerebrovascular risk factors.

Methotrexate has also been shown to provide some benefit as an adjunctive therapy in GCA, but the effect in studies has been modest at best, and treatment has been disappointing in practice, Dr. Seo said.

Three randomized, double-blind, placebo-controlled trials of methotrexate in this disease had three different results. A meta-analysis of the findings suggested that methotrexate reduced the probability of a first relapse modestly (hazard ratio, 0.65) during nearly 55 weeks of follow-up, and showed that it also reduced the corticosteroid cumulative dose by more than 800 mg on average over 48 weeks (Arthritis Rheum. 2007;56:2789-97). That reduction, however, was not associated with a reduction in steroid side effects, he said.

Still, the beneficial effects are more promising than those seen with infliximab, which has not been found to have benefit in GCA. In fact, a randomized, placebo-controlled, phase II trial that was scheduled to run for about 1 year closed after only 22 weeks because of lack of efficacy in the treatment group, Dr. Seo noted (Ann. Intern. Med. 2007;146:621-30).

Patients in that trial received prednisone/prednisolone and either placebo or 5 mg/kg infliximab infusions. The infusions were given at baseline and were planned for weeks 2, 6, 14, 22, 30, 38, and 46 (with prednisone tapering after randomization in both groups). At the time the study was discontinued, no difference was seen in the proportion of relapse-free subjects, time to first relapse, or cumulative prednisone dose between the two groups.

The findings were somewhat surprising, given that infliximab works so well for so many other forms of large vessel vasculitis, Dr. Seo said.

"Despite the fact that it should work, it doesn’t seem to for GCA," he said.

So for now, the best bet for adjunctive treatment in GCA is aspirin, which "seems to be a very good idea," he said, noting that although it is not yet the standard of care, it may eventually become so.

Methotrexate can be considered as an adjunctive therapeutic option based on the available data, but it has only a small impact, and the question of whether it should be standard remains controversial. Infliximab is "hard to recommend" in GCA, he said adding that the search continues for effective treatments.

Drugs under investigation for GCA include abatacept and tocilizumab, but it remains too early to say if these will be helpful, he noted.

Dr. Seo disclosed that he has received consulting fees and other remuneration from Genentech.

CHICAGO – Glucocorticoids remain the cornerstone of therapy for giant cell arteritis, but aspirin and methotrexate can be useful as adjunctive therapies.

Infliximab, however, does not appear to be of benefit in this disease, said Dr. Philip Seo at a symposium sponsored by the American College of Rheumatology.

The benefits of aspirin were demonstrated in a 2004 retrospective study of 175 patients with giant cell arteritis (GCA), including 36 who were being treated with 100 mg/day of aspirin from the time of diagnosis and 139 who were not (Arthritis Rheum. 2004;50:1332-7). Aspirin was shown to be associated with a reduced risk of cranial ischemic events, including acute vision loss and cerebrovascular accident, said Dr. Seo, codirector of the vasculitis center at the Johns Hopkins University, Baltimore.

In that study, only 8% of patients who were treated with aspirin, compared with 29% of those not treated with aspirin, experienced a cranial ischemic event, and that was despite the fact that cerebrovascular risk factors were present in 38.9% and 20% of patients, respectively. In 166 patients from the study who were followed for at least 3 months, the findings were similar: In all, 2.7% of 73 patients treated with aspirin, compared with 12.9% of those not treated with aspirin, experienced a cerebral ischemic event during follow-up, despite 28.8% and 12.9% in the groups, respectively, having cerebrovascular risk factors.

Methotrexate has also been shown to provide some benefit as an adjunctive therapy in GCA, but the effect in studies has been modest at best, and treatment has been disappointing in practice, Dr. Seo said.

Three randomized, double-blind, placebo-controlled trials of methotrexate in this disease had three different results. A meta-analysis of the findings suggested that methotrexate reduced the probability of a first relapse modestly (hazard ratio, 0.65) during nearly 55 weeks of follow-up, and showed that it also reduced the corticosteroid cumulative dose by more than 800 mg on average over 48 weeks (Arthritis Rheum. 2007;56:2789-97). That reduction, however, was not associated with a reduction in steroid side effects, he said.

Still, the beneficial effects are more promising than those seen with infliximab, which has not been found to have benefit in GCA. In fact, a randomized, placebo-controlled, phase II trial that was scheduled to run for about 1 year closed after only 22 weeks because of lack of efficacy in the treatment group, Dr. Seo noted (Ann. Intern. Med. 2007;146:621-30).

Patients in that trial received prednisone/prednisolone and either placebo or 5 mg/kg infliximab infusions. The infusions were given at baseline and were planned for weeks 2, 6, 14, 22, 30, 38, and 46 (with prednisone tapering after randomization in both groups). At the time the study was discontinued, no difference was seen in the proportion of relapse-free subjects, time to first relapse, or cumulative prednisone dose between the two groups.

The findings were somewhat surprising, given that infliximab works so well for so many other forms of large vessel vasculitis, Dr. Seo said.

"Despite the fact that it should work, it doesn’t seem to for GCA," he said.

So for now, the best bet for adjunctive treatment in GCA is aspirin, which "seems to be a very good idea," he said, noting that although it is not yet the standard of care, it may eventually become so.

Methotrexate can be considered as an adjunctive therapeutic option based on the available data, but it has only a small impact, and the question of whether it should be standard remains controversial. Infliximab is "hard to recommend" in GCA, he said adding that the search continues for effective treatments.

Drugs under investigation for GCA include abatacept and tocilizumab, but it remains too early to say if these will be helpful, he noted.

Dr. Seo disclosed that he has received consulting fees and other remuneration from Genentech.

CHICAGO – Glucocorticoids remain the cornerstone of therapy for giant cell arteritis, but aspirin and methotrexate can be useful as adjunctive therapies.

Infliximab, however, does not appear to be of benefit in this disease, said Dr. Philip Seo at a symposium sponsored by the American College of Rheumatology.

The benefits of aspirin were demonstrated in a 2004 retrospective study of 175 patients with giant cell arteritis (GCA), including 36 who were being treated with 100 mg/day of aspirin from the time of diagnosis and 139 who were not (Arthritis Rheum. 2004;50:1332-7). Aspirin was shown to be associated with a reduced risk of cranial ischemic events, including acute vision loss and cerebrovascular accident, said Dr. Seo, codirector of the vasculitis center at the Johns Hopkins University, Baltimore.

In that study, only 8% of patients who were treated with aspirin, compared with 29% of those not treated with aspirin, experienced a cranial ischemic event, and that was despite the fact that cerebrovascular risk factors were present in 38.9% and 20% of patients, respectively. In 166 patients from the study who were followed for at least 3 months, the findings were similar: In all, 2.7% of 73 patients treated with aspirin, compared with 12.9% of those not treated with aspirin, experienced a cerebral ischemic event during follow-up, despite 28.8% and 12.9% in the groups, respectively, having cerebrovascular risk factors.

Methotrexate has also been shown to provide some benefit as an adjunctive therapy in GCA, but the effect in studies has been modest at best, and treatment has been disappointing in practice, Dr. Seo said.

Three randomized, double-blind, placebo-controlled trials of methotrexate in this disease had three different results. A meta-analysis of the findings suggested that methotrexate reduced the probability of a first relapse modestly (hazard ratio, 0.65) during nearly 55 weeks of follow-up, and showed that it also reduced the corticosteroid cumulative dose by more than 800 mg on average over 48 weeks (Arthritis Rheum. 2007;56:2789-97). That reduction, however, was not associated with a reduction in steroid side effects, he said.

Still, the beneficial effects are more promising than those seen with infliximab, which has not been found to have benefit in GCA. In fact, a randomized, placebo-controlled, phase II trial that was scheduled to run for about 1 year closed after only 22 weeks because of lack of efficacy in the treatment group, Dr. Seo noted (Ann. Intern. Med. 2007;146:621-30).

Patients in that trial received prednisone/prednisolone and either placebo or 5 mg/kg infliximab infusions. The infusions were given at baseline and were planned for weeks 2, 6, 14, 22, 30, 38, and 46 (with prednisone tapering after randomization in both groups). At the time the study was discontinued, no difference was seen in the proportion of relapse-free subjects, time to first relapse, or cumulative prednisone dose between the two groups.

The findings were somewhat surprising, given that infliximab works so well for so many other forms of large vessel vasculitis, Dr. Seo said.

"Despite the fact that it should work, it doesn’t seem to for GCA," he said.

So for now, the best bet for adjunctive treatment in GCA is aspirin, which "seems to be a very good idea," he said, noting that although it is not yet the standard of care, it may eventually become so.

Methotrexate can be considered as an adjunctive therapeutic option based on the available data, but it has only a small impact, and the question of whether it should be standard remains controversial. Infliximab is "hard to recommend" in GCA, he said adding that the search continues for effective treatments.

Drugs under investigation for GCA include abatacept and tocilizumab, but it remains too early to say if these will be helpful, he noted.

Dr. Seo disclosed that he has received consulting fees and other remuneration from Genentech.

CHICAGO – Glucocorticoids remain the cornerstone of therapy for giant cell arteritis, but aspirin and methotrexate can be useful as adjunctive therapies.

Infliximab, however, does not appear to be of benefit in this disease, said Dr. Philip Seo at a symposium sponsored by the American College of Rheumatology.

The benefits of aspirin were demonstrated in a 2004 retrospective study of 175 patients with giant cell arteritis (GCA), including 36 who were being treated with 100 mg/day of aspirin from the time of diagnosis and 139 who were not (Arthritis Rheum. 2004;50:1332-7). Aspirin was shown to be associated with a reduced risk of cranial ischemic events, including acute vision loss and cerebrovascular accident, said Dr. Seo, codirector of the vasculitis center at the Johns Hopkins University, Baltimore.

In that study, only 8% of patients who were treated with aspirin, compared with 29% of those not treated with aspirin, experienced a cranial ischemic event, and that was despite the fact that cerebrovascular risk factors were present in 38.9% and 20% of patients, respectively. In 166 patients from the study who were followed for at least 3 months, the findings were similar: In all, 2.7% of 73 patients treated with aspirin, compared with 12.9% of those not treated with aspirin, experienced a cerebral ischemic event during follow-up, despite 28.8% and 12.9% in the groups, respectively, having cerebrovascular risk factors.

Methotrexate has also been shown to provide some benefit as an adjunctive therapy in GCA, but the effect in studies has been modest at best, and treatment has been disappointing in practice, Dr. Seo said.

Three randomized, double-blind, placebo-controlled trials of methotrexate in this disease had three different results. A meta-analysis of the findings suggested that methotrexate reduced the probability of a first relapse modestly (hazard ratio, 0.65) during nearly 55 weeks of follow-up, and showed that it also reduced the corticosteroid cumulative dose by more than 800 mg on average over 48 weeks (Arthritis Rheum. 2007;56:2789-97). That reduction, however, was not associated with a reduction in steroid side effects, he said.

Still, the beneficial effects are more promising than those seen with infliximab, which has not been found to have benefit in GCA. In fact, a randomized, placebo-controlled, phase II trial that was scheduled to run for about 1 year closed after only 22 weeks because of lack of efficacy in the treatment group, Dr. Seo noted (Ann. Intern. Med. 2007;146:621-30).

Patients in that trial received prednisone/prednisolone and either placebo or 5 mg/kg infliximab infusions. The infusions were given at baseline and were planned for weeks 2, 6, 14, 22, 30, 38, and 46 (with prednisone tapering after randomization in both groups). At the time the study was discontinued, no difference was seen in the proportion of relapse-free subjects, time to first relapse, or cumulative prednisone dose between the two groups.

The findings were somewhat surprising, given that infliximab works so well for so many other forms of large vessel vasculitis, Dr. Seo said.

"Despite the fact that it should work, it doesn’t seem to for GCA," he said.

So for now, the best bet for adjunctive treatment in GCA is aspirin, which "seems to be a very good idea," he said, noting that although it is not yet the standard of care, it may eventually become so.

Methotrexate can be considered as an adjunctive therapeutic option based on the available data, but it has only a small impact, and the question of whether it should be standard remains controversial. Infliximab is "hard to recommend" in GCA, he said adding that the search continues for effective treatments.

Drugs under investigation for GCA include abatacept and tocilizumab, but it remains too early to say if these will be helpful, he noted.

Dr. Seo disclosed that he has received consulting fees and other remuneration from Genentech.

CHICAGO – Glucocorticoids remain the cornerstone of therapy for giant cell arteritis, but aspirin and methotrexate can be useful as adjunctive therapies.

Infliximab, however, does not appear to be of benefit in this disease, said Dr. Philip Seo at a symposium sponsored by the American College of Rheumatology.

The benefits of aspirin were demonstrated in a 2004 retrospective study of 175 patients with giant cell arteritis (GCA), including 36 who were being treated with 100 mg/day of aspirin from the time of diagnosis and 139 who were not (Arthritis Rheum. 2004;50:1332-7). Aspirin was shown to be associated with a reduced risk of cranial ischemic events, including acute vision loss and cerebrovascular accident, said Dr. Seo, codirector of the vasculitis center at the Johns Hopkins University, Baltimore.

In that study, only 8% of patients who were treated with aspirin, compared with 29% of those not treated with aspirin, experienced a cranial ischemic event, and that was despite the fact that cerebrovascular risk factors were present in 38.9% and 20% of patients, respectively. In 166 patients from the study who were followed for at least 3 months, the findings were similar: In all, 2.7% of 73 patients treated with aspirin, compared with 12.9% of those not treated with aspirin, experienced a cerebral ischemic event during follow-up, despite 28.8% and 12.9% in the groups, respectively, having cerebrovascular risk factors.

Methotrexate has also been shown to provide some benefit as an adjunctive therapy in GCA, but the effect in studies has been modest at best, and treatment has been disappointing in practice, Dr. Seo said.

Three randomized, double-blind, placebo-controlled trials of methotrexate in this disease had three different results. A meta-analysis of the findings suggested that methotrexate reduced the probability of a first relapse modestly (hazard ratio, 0.65) during nearly 55 weeks of follow-up, and showed that it also reduced the corticosteroid cumulative dose by more than 800 mg on average over 48 weeks (Arthritis Rheum. 2007;56:2789-97). That reduction, however, was not associated with a reduction in steroid side effects, he said.

Still, the beneficial effects are more promising than those seen with infliximab, which has not been found to have benefit in GCA. In fact, a randomized, placebo-controlled, phase II trial that was scheduled to run for about 1 year closed after only 22 weeks because of lack of efficacy in the treatment group, Dr. Seo noted (Ann. Intern. Med. 2007;146:621-30).

Patients in that trial received prednisone/prednisolone and either placebo or 5 mg/kg infliximab infusions. The infusions were given at baseline and were planned for weeks 2, 6, 14, 22, 30, 38, and 46 (with prednisone tapering after randomization in both groups). At the time the study was discontinued, no difference was seen in the proportion of relapse-free subjects, time to first relapse, or cumulative prednisone dose between the two groups.

The findings were somewhat surprising, given that infliximab works so well for so many other forms of large vessel vasculitis, Dr. Seo said.

"Despite the fact that it should work, it doesn’t seem to for GCA," he said.

So for now, the best bet for adjunctive treatment in GCA is aspirin, which "seems to be a very good idea," he said, noting that although it is not yet the standard of care, it may eventually become so.

Methotrexate can be considered as an adjunctive therapeutic option based on the available data, but it has only a small impact, and the question of whether it should be standard remains controversial. Infliximab is "hard to recommend" in GCA, he said adding that the search continues for effective treatments.

Drugs under investigation for GCA include abatacept and tocilizumab, but it remains too early to say if these will be helpful, he noted.

Dr. Seo disclosed that he has received consulting fees and other remuneration from Genentech.

CHICAGO – Glucocorticoids remain the cornerstone of therapy for giant cell arteritis, but aspirin and methotrexate can be useful as adjunctive therapies.

Infliximab, however, does not appear to be of benefit in this disease, said Dr. Philip Seo at a symposium sponsored by the American College of Rheumatology.

The benefits of aspirin were demonstrated in a 2004 retrospective study of 175 patients with giant cell arteritis (GCA), including 36 who were being treated with 100 mg/day of aspirin from the time of diagnosis and 139 who were not (Arthritis Rheum. 2004;50:1332-7). Aspirin was shown to be associated with a reduced risk of cranial ischemic events, including acute vision loss and cerebrovascular accident, said Dr. Seo, codirector of the vasculitis center at the Johns Hopkins University, Baltimore.

In that study, only 8% of patients who were treated with aspirin, compared with 29% of those not treated with aspirin, experienced a cranial ischemic event, and that was despite the fact that cerebrovascular risk factors were present in 38.9% and 20% of patients, respectively. In 166 patients from the study who were followed for at least 3 months, the findings were similar: In all, 2.7% of 73 patients treated with aspirin, compared with 12.9% of those not treated with aspirin, experienced a cerebral ischemic event during follow-up, despite 28.8% and 12.9% in the groups, respectively, having cerebrovascular risk factors.

Methotrexate has also been shown to provide some benefit as an adjunctive therapy in GCA, but the effect in studies has been modest at best, and treatment has been disappointing in practice, Dr. Seo said.

Three randomized, double-blind, placebo-controlled trials of methotrexate in this disease had three different results. A meta-analysis of the findings suggested that methotrexate reduced the probability of a first relapse modestly (hazard ratio, 0.65) during nearly 55 weeks of follow-up, and showed that it also reduced the corticosteroid cumulative dose by more than 800 mg on average over 48 weeks (Arthritis Rheum. 2007;56:2789-97). That reduction, however, was not associated with a reduction in steroid side effects, he said.

Still, the beneficial effects are more promising than those seen with infliximab, which has not been found to have benefit in GCA. In fact, a randomized, placebo-controlled, phase II trial that was scheduled to run for about 1 year closed after only 22 weeks because of lack of efficacy in the treatment group, Dr. Seo noted (Ann. Intern. Med. 2007;146:621-30).

Patients in that trial received prednisone/prednisolone and either placebo or 5 mg/kg infliximab infusions. The infusions were given at baseline and were planned for weeks 2, 6, 14, 22, 30, 38, and 46 (with prednisone tapering after randomization in both groups). At the time the study was discontinued, no difference was seen in the proportion of relapse-free subjects, time to first relapse, or cumulative prednisone dose between the two groups.

The findings were somewhat surprising, given that infliximab works so well for so many other forms of large vessel vasculitis, Dr. Seo said.

"Despite the fact that it should work, it doesn’t seem to for GCA," he said.

So for now, the best bet for adjunctive treatment in GCA is aspirin, which "seems to be a very good idea," he said, noting that although it is not yet the standard of care, it may eventually become so.

Methotrexate can be considered as an adjunctive therapeutic option based on the available data, but it has only a small impact, and the question of whether it should be standard remains controversial. Infliximab is "hard to recommend" in GCA, he said adding that the search continues for effective treatments.

Drugs under investigation for GCA include abatacept and tocilizumab, but it remains too early to say if these will be helpful, he noted.

Dr. Seo disclosed that he has received consulting fees and other remuneration from Genentech.

CHICAGO – A diagnosis of autoimmune hepatitis does not necessarily mandate therapy.

Rather, a decision about therapy should be based on the natural history of the disease, Dr. Bruce Luxon said at a symposium sponsored by the American College of Rheumatology.

Patients for whom treatment is mandatory are those with aspartate aminotransferase (AST) levels greater than 10 times the upper limit of normal, or 5 times the upper limit of normal plus gamma globulin levels greater than twice the upper limit of normal. Data from the 1970s showed that patients with these disease characteristics had a 6-month mortality of 60%, said Dr. Luxon, professor and chair of the department of internal medicine at Georgetown University, Washington.

Similarly, treatment is needed when a biopsy shows "bridging" – or multilobular – necrosis, as studies have shown that progression to cirrhosis occurs in more than 80% of such patients, and 5-year mortality is about 45%.

"In contrast, there is a group of patients whose AST and [alanine transaminase (ALT)] were quite normal or very close to normal [less than twice the normal value]. Those people had a 10-year life expectancy greater than 80%," he said, noting that these patients generally don’t require treatment.

Cirrhotic patients with significant inflammation, on the other hand, might benefit from a 3-6 month trial of therapy to slow down progression, he said adding: "That’s really a decision for a hepatologist to make."

In those who will be treated, prednisone remains the mainstay of therapy, as it has for 50 years, he noted.

It is given initially at a high dose of 60 mg for the first week (or 30 mg plus 50 mg of azathioprine, which is usually given to allow lowering of the prednisone dose). Prednisone is lowered to 40 mg for week 2 (or 20 mg and 50 mg of prednisone and azathioprine, respectively), and to 30 mg for weeks 3 and 4 (or 15 mg and 50 mg of prednisone and azathioprine, respectively).

After week 4, the dose remains 20 mg (or 10 mg and 50 mg of prednisone and azathioprine, respectively) until the clinical end point is reached.

Use of the combination therapy is associated with a much lower occurrence of corticosteroid-related side effects (10% vs. 44%), but not all patients can tolerate the azathioprine. It is fine to give prednisone monotherapy in such patients, he said.

The typical side effects of steroid therapy can occur, including weight gain, unwanted hair growth, acne, and – importantly – bone disease.

"You really want to make sure they are on calcium and vitamin D," he said, noting bisphosphonates, rather than controversial estrogen replacement, are usually prescribed as well.

Azathioprine side effects can include gastrointestinal upset, drug-induced hepatitis in rare cases, and cancer in very rare cases.

The efficacy of treatment should be evaluated on a biochemical or histological basis. But keep in mind that while a failure to normalize liver enzymes suggests residual disease, about half of those who do have normalization will still go on to have significant liver fibrosis and inflammation on biopsy. "So it’s not sufficient to just normalize transaminases," he said.

Since biopsy improvement lags behind biochemical improvement by about 6 months, a repeat biopsy at that time is warranted.

These serial biopsies, which are important in this disease, can also predict whether a patient can be taken off therapy, he said.

Patients with a normal liver biopsy at follow-up will have only about a 15%-20% risk of relapse, so it is reasonable to take them off treatment, he noted.

Conversely, those with interface hepatitis and inflammation on follow-up biopsy will relapse about 90% of the time and require ongoing treatment.

In most cases, autoimmune hepatitis can be controlled, although ongoing treatment might be required. About 65% of patients will remit within 18 months, while only about 10% of patients will fail treatment altogether – and those patients typically have other contributing factors, such as excessive alcohol use, concurrent viral infection such as hepatitis B or C, or an overlap syndrome.

Another 10% of patients won’t tolerate treatment.

Among those who require treatment indefinitely because of relapse, maintenance therapy with 7.5 mg/day of prednisone and 2 mg per kg/day of azathioprine can be effective for maintaining control. In one study, 85% of patients who relapsed were managed effectively with this strategy at a mean follow-up of 149 months, Dr. Luxon noted.

These patients generally have survival similar to age- and gender-matched controls, so although they have to stay on these low doses of treatment for life, the treatment is quite effective.

In those who fail therapy, it might be useful to increase prednisone to 60 mg/day and azathioprine to 150 mg/day. If there is still no response, it is worth trying mycophenolate mofetil or a calcineurin inhibitor such as tacrolimus, although these have only been assessed in small pilot studies and haven’t proved very successful. Transplant is also an option that generally works well for autoimmune hepatitis in patients who don’t respond to medical therapy and can be considered, particularly in young patients with otherwise good health, Dr. Luxon said.

Dr. Luxon had no relevant disclosures to report.

CHICAGO – A diagnosis of autoimmune hepatitis does not necessarily mandate therapy.

Rather, a decision about therapy should be based on the natural history of the disease, Dr. Bruce Luxon said at a symposium sponsored by the American College of Rheumatology.

Patients for whom treatment is mandatory are those with aspartate aminotransferase (AST) levels greater than 10 times the upper limit of normal, or 5 times the upper limit of normal plus gamma globulin levels greater than twice the upper limit of normal. Data from the 1970s showed that patients with these disease characteristics had a 6-month mortality of 60%, said Dr. Luxon, professor and chair of the department of internal medicine at Georgetown University, Washington.

Similarly, treatment is needed when a biopsy shows "bridging" – or multilobular – necrosis, as studies have shown that progression to cirrhosis occurs in more than 80% of such patients, and 5-year mortality is about 45%.

"In contrast, there is a group of patients whose AST and [alanine transaminase (ALT)] were quite normal or very close to normal [less than twice the normal value]. Those people had a 10-year life expectancy greater than 80%," he said, noting that these patients generally don’t require treatment.

Cirrhotic patients with significant inflammation, on the other hand, might benefit from a 3-6 month trial of therapy to slow down progression, he said adding: "That’s really a decision for a hepatologist to make."

In those who will be treated, prednisone remains the mainstay of therapy, as it has for 50 years, he noted.

It is given initially at a high dose of 60 mg for the first week (or 30 mg plus 50 mg of azathioprine, which is usually given to allow lowering of the prednisone dose). Prednisone is lowered to 40 mg for week 2 (or 20 mg and 50 mg of prednisone and azathioprine, respectively), and to 30 mg for weeks 3 and 4 (or 15 mg and 50 mg of prednisone and azathioprine, respectively).

After week 4, the dose remains 20 mg (or 10 mg and 50 mg of prednisone and azathioprine, respectively) until the clinical end point is reached.

Use of the combination therapy is associated with a much lower occurrence of corticosteroid-related side effects (10% vs. 44%), but not all patients can tolerate the azathioprine. It is fine to give prednisone monotherapy in such patients, he said.

The typical side effects of steroid therapy can occur, including weight gain, unwanted hair growth, acne, and – importantly – bone disease.

"You really want to make sure they are on calcium and vitamin D," he said, noting bisphosphonates, rather than controversial estrogen replacement, are usually prescribed as well.

Azathioprine side effects can include gastrointestinal upset, drug-induced hepatitis in rare cases, and cancer in very rare cases.

The efficacy of treatment should be evaluated on a biochemical or histological basis. But keep in mind that while a failure to normalize liver enzymes suggests residual disease, about half of those who do have normalization will still go on to have significant liver fibrosis and inflammation on biopsy. "So it’s not sufficient to just normalize transaminases," he said.

Since biopsy improvement lags behind biochemical improvement by about 6 months, a repeat biopsy at that time is warranted.

These serial biopsies, which are important in this disease, can also predict whether a patient can be taken off therapy, he said.

Patients with a normal liver biopsy at follow-up will have only about a 15%-20% risk of relapse, so it is reasonable to take them off treatment, he noted.

Conversely, those with interface hepatitis and inflammation on follow-up biopsy will relapse about 90% of the time and require ongoing treatment.

In most cases, autoimmune hepatitis can be controlled, although ongoing treatment might be required. About 65% of patients will remit within 18 months, while only about 10% of patients will fail treatment altogether – and those patients typically have other contributing factors, such as excessive alcohol use, concurrent viral infection such as hepatitis B or C, or an overlap syndrome.

Another 10% of patients won’t tolerate treatment.

Among those who require treatment indefinitely because of relapse, maintenance therapy with 7.5 mg/day of prednisone and 2 mg per kg/day of azathioprine can be effective for maintaining control. In one study, 85% of patients who relapsed were managed effectively with this strategy at a mean follow-up of 149 months, Dr. Luxon noted.

These patients generally have survival similar to age- and gender-matched controls, so although they have to stay on these low doses of treatment for life, the treatment is quite effective.

In those who fail therapy, it might be useful to increase prednisone to 60 mg/day and azathioprine to 150 mg/day. If there is still no response, it is worth trying mycophenolate mofetil or a calcineurin inhibitor such as tacrolimus, although these have only been assessed in small pilot studies and haven’t proved very successful. Transplant is also an option that generally works well for autoimmune hepatitis in patients who don’t respond to medical therapy and can be considered, particularly in young patients with otherwise good health, Dr. Luxon said.

Dr. Luxon had no relevant disclosures to report.

CHICAGO – A diagnosis of autoimmune hepatitis does not necessarily mandate therapy.

Rather, a decision about therapy should be based on the natural history of the disease, Dr. Bruce Luxon said at a symposium sponsored by the American College of Rheumatology.

Patients for whom treatment is mandatory are those with aspartate aminotransferase (AST) levels greater than 10 times the upper limit of normal, or 5 times the upper limit of normal plus gamma globulin levels greater than twice the upper limit of normal. Data from the 1970s showed that patients with these disease characteristics had a 6-month mortality of 60%, said Dr. Luxon, professor and chair of the department of internal medicine at Georgetown University, Washington.

Similarly, treatment is needed when a biopsy shows "bridging" – or multilobular – necrosis, as studies have shown that progression to cirrhosis occurs in more than 80% of such patients, and 5-year mortality is about 45%.

"In contrast, there is a group of patients whose AST and [alanine transaminase (ALT)] were quite normal or very close to normal [less than twice the normal value]. Those people had a 10-year life expectancy greater than 80%," he said, noting that these patients generally don’t require treatment.

Cirrhotic patients with significant inflammation, on the other hand, might benefit from a 3-6 month trial of therapy to slow down progression, he said adding: "That’s really a decision for a hepatologist to make."

In those who will be treated, prednisone remains the mainstay of therapy, as it has for 50 years, he noted.

It is given initially at a high dose of 60 mg for the first week (or 30 mg plus 50 mg of azathioprine, which is usually given to allow lowering of the prednisone dose). Prednisone is lowered to 40 mg for week 2 (or 20 mg and 50 mg of prednisone and azathioprine, respectively), and to 30 mg for weeks 3 and 4 (or 15 mg and 50 mg of prednisone and azathioprine, respectively).

After week 4, the dose remains 20 mg (or 10 mg and 50 mg of prednisone and azathioprine, respectively) until the clinical end point is reached.

Use of the combination therapy is associated with a much lower occurrence of corticosteroid-related side effects (10% vs. 44%), but not all patients can tolerate the azathioprine. It is fine to give prednisone monotherapy in such patients, he said.

The typical side effects of steroid therapy can occur, including weight gain, unwanted hair growth, acne, and – importantly – bone disease.

"You really want to make sure they are on calcium and vitamin D," he said, noting bisphosphonates, rather than controversial estrogen replacement, are usually prescribed as well.

Azathioprine side effects can include gastrointestinal upset, drug-induced hepatitis in rare cases, and cancer in very rare cases.

The efficacy of treatment should be evaluated on a biochemical or histological basis. But keep in mind that while a failure to normalize liver enzymes suggests residual disease, about half of those who do have normalization will still go on to have significant liver fibrosis and inflammation on biopsy. "So it’s not sufficient to just normalize transaminases," he said.

Since biopsy improvement lags behind biochemical improvement by about 6 months, a repeat biopsy at that time is warranted.

These serial biopsies, which are important in this disease, can also predict whether a patient can be taken off therapy, he said.

Patients with a normal liver biopsy at follow-up will have only about a 15%-20% risk of relapse, so it is reasonable to take them off treatment, he noted.

Conversely, those with interface hepatitis and inflammation on follow-up biopsy will relapse about 90% of the time and require ongoing treatment.

In most cases, autoimmune hepatitis can be controlled, although ongoing treatment might be required. About 65% of patients will remit within 18 months, while only about 10% of patients will fail treatment altogether – and those patients typically have other contributing factors, such as excessive alcohol use, concurrent viral infection such as hepatitis B or C, or an overlap syndrome.

Another 10% of patients won’t tolerate treatment.

Among those who require treatment indefinitely because of relapse, maintenance therapy with 7.5 mg/day of prednisone and 2 mg per kg/day of azathioprine can be effective for maintaining control. In one study, 85% of patients who relapsed were managed effectively with this strategy at a mean follow-up of 149 months, Dr. Luxon noted.

These patients generally have survival similar to age- and gender-matched controls, so although they have to stay on these low doses of treatment for life, the treatment is quite effective.

In those who fail therapy, it might be useful to increase prednisone to 60 mg/day and azathioprine to 150 mg/day. If there is still no response, it is worth trying mycophenolate mofetil or a calcineurin inhibitor such as tacrolimus, although these have only been assessed in small pilot studies and haven’t proved very successful. Transplant is also an option that generally works well for autoimmune hepatitis in patients who don’t respond to medical therapy and can be considered, particularly in young patients with otherwise good health, Dr. Luxon said.

Dr. Luxon had no relevant disclosures to report.

CHICAGO – A diagnosis of autoimmune hepatitis does not necessarily mandate therapy.

Rather, a decision about therapy should be based on the natural history of the disease, Dr. Bruce Luxon said at a symposium sponsored by the American College of Rheumatology.

Patients for whom treatment is mandatory are those with aspartate aminotransferase (AST) levels greater than 10 times the upper limit of normal, or 5 times the upper limit of normal plus gamma globulin levels greater than twice the upper limit of normal. Data from the 1970s showed that patients with these disease characteristics had a 6-month mortality of 60%, said Dr. Luxon, professor and chair of the department of internal medicine at Georgetown University, Washington.

Similarly, treatment is needed when a biopsy shows "bridging" – or multilobular – necrosis, as studies have shown that progression to cirrhosis occurs in more than 80% of such patients, and 5-year mortality is about 45%.

"In contrast, there is a group of patients whose AST and [alanine transaminase (ALT)] were quite normal or very close to normal [less than twice the normal value]. Those people had a 10-year life expectancy greater than 80%," he said, noting that these patients generally don’t require treatment.

Cirrhotic patients with significant inflammation, on the other hand, might benefit from a 3-6 month trial of therapy to slow down progression, he said adding: "That’s really a decision for a hepatologist to make."

In those who will be treated, prednisone remains the mainstay of therapy, as it has for 50 years, he noted.

It is given initially at a high dose of 60 mg for the first week (or 30 mg plus 50 mg of azathioprine, which is usually given to allow lowering of the prednisone dose). Prednisone is lowered to 40 mg for week 2 (or 20 mg and 50 mg of prednisone and azathioprine, respectively), and to 30 mg for weeks 3 and 4 (or 15 mg and 50 mg of prednisone and azathioprine, respectively).

After week 4, the dose remains 20 mg (or 10 mg and 50 mg of prednisone and azathioprine, respectively) until the clinical end point is reached.

Use of the combination therapy is associated with a much lower occurrence of corticosteroid-related side effects (10% vs. 44%), but not all patients can tolerate the azathioprine. It is fine to give prednisone monotherapy in such patients, he said.

The typical side effects of steroid therapy can occur, including weight gain, unwanted hair growth, acne, and – importantly – bone disease.

"You really want to make sure they are on calcium and vitamin D," he said, noting bisphosphonates, rather than controversial estrogen replacement, are usually prescribed as well.

Azathioprine side effects can include gastrointestinal upset, drug-induced hepatitis in rare cases, and cancer in very rare cases.

The efficacy of treatment should be evaluated on a biochemical or histological basis. But keep in mind that while a failure to normalize liver enzymes suggests residual disease, about half of those who do have normalization will still go on to have significant liver fibrosis and inflammation on biopsy. "So it’s not sufficient to just normalize transaminases," he said.

Since biopsy improvement lags behind biochemical improvement by about 6 months, a repeat biopsy at that time is warranted.

These serial biopsies, which are important in this disease, can also predict whether a patient can be taken off therapy, he said.

Patients with a normal liver biopsy at follow-up will have only about a 15%-20% risk of relapse, so it is reasonable to take them off treatment, he noted.

Conversely, those with interface hepatitis and inflammation on follow-up biopsy will relapse about 90% of the time and require ongoing treatment.

In most cases, autoimmune hepatitis can be controlled, although ongoing treatment might be required. About 65% of patients will remit within 18 months, while only about 10% of patients will fail treatment altogether – and those patients typically have other contributing factors, such as excessive alcohol use, concurrent viral infection such as hepatitis B or C, or an overlap syndrome.

Another 10% of patients won’t tolerate treatment.

Among those who require treatment indefinitely because of relapse, maintenance therapy with 7.5 mg/day of prednisone and 2 mg per kg/day of azathioprine can be effective for maintaining control. In one study, 85% of patients who relapsed were managed effectively with this strategy at a mean follow-up of 149 months, Dr. Luxon noted.

These patients generally have survival similar to age- and gender-matched controls, so although they have to stay on these low doses of treatment for life, the treatment is quite effective.

In those who fail therapy, it might be useful to increase prednisone to 60 mg/day and azathioprine to 150 mg/day. If there is still no response, it is worth trying mycophenolate mofetil or a calcineurin inhibitor such as tacrolimus, although these have only been assessed in small pilot studies and haven’t proved very successful. Transplant is also an option that generally works well for autoimmune hepatitis in patients who don’t respond to medical therapy and can be considered, particularly in young patients with otherwise good health, Dr. Luxon said.

Dr. Luxon had no relevant disclosures to report.

CHICAGO – A diagnosis of autoimmune hepatitis does not necessarily mandate therapy.

Rather, a decision about therapy should be based on the natural history of the disease, Dr. Bruce Luxon said at a symposium sponsored by the American College of Rheumatology.

Patients for whom treatment is mandatory are those with aspartate aminotransferase (AST) levels greater than 10 times the upper limit of normal, or 5 times the upper limit of normal plus gamma globulin levels greater than twice the upper limit of normal. Data from the 1970s showed that patients with these disease characteristics had a 6-month mortality of 60%, said Dr. Luxon, professor and chair of the department of internal medicine at Georgetown University, Washington.

Similarly, treatment is needed when a biopsy shows "bridging" – or multilobular – necrosis, as studies have shown that progression to cirrhosis occurs in more than 80% of such patients, and 5-year mortality is about 45%.

"In contrast, there is a group of patients whose AST and [alanine transaminase (ALT)] were quite normal or very close to normal [less than twice the normal value]. Those people had a 10-year life expectancy greater than 80%," he said, noting that these patients generally don’t require treatment.

Cirrhotic patients with significant inflammation, on the other hand, might benefit from a 3-6 month trial of therapy to slow down progression, he said adding: "That’s really a decision for a hepatologist to make."

In those who will be treated, prednisone remains the mainstay of therapy, as it has for 50 years, he noted.

It is given initially at a high dose of 60 mg for the first week (or 30 mg plus 50 mg of azathioprine, which is usually given to allow lowering of the prednisone dose). Prednisone is lowered to 40 mg for week 2 (or 20 mg and 50 mg of prednisone and azathioprine, respectively), and to 30 mg for weeks 3 and 4 (or 15 mg and 50 mg of prednisone and azathioprine, respectively).

After week 4, the dose remains 20 mg (or 10 mg and 50 mg of prednisone and azathioprine, respectively) until the clinical end point is reached.

Use of the combination therapy is associated with a much lower occurrence of corticosteroid-related side effects (10% vs. 44%), but not all patients can tolerate the azathioprine. It is fine to give prednisone monotherapy in such patients, he said.

The typical side effects of steroid therapy can occur, including weight gain, unwanted hair growth, acne, and – importantly – bone disease.

"You really want to make sure they are on calcium and vitamin D," he said, noting bisphosphonates, rather than controversial estrogen replacement, are usually prescribed as well.

Azathioprine side effects can include gastrointestinal upset, drug-induced hepatitis in rare cases, and cancer in very rare cases.

The efficacy of treatment should be evaluated on a biochemical or histological basis. But keep in mind that while a failure to normalize liver enzymes suggests residual disease, about half of those who do have normalization will still go on to have significant liver fibrosis and inflammation on biopsy. "So it’s not sufficient to just normalize transaminases," he said.

Since biopsy improvement lags behind biochemical improvement by about 6 months, a repeat biopsy at that time is warranted.

These serial biopsies, which are important in this disease, can also predict whether a patient can be taken off therapy, he said.

Patients with a normal liver biopsy at follow-up will have only about a 15%-20% risk of relapse, so it is reasonable to take them off treatment, he noted.

Conversely, those with interface hepatitis and inflammation on follow-up biopsy will relapse about 90% of the time and require ongoing treatment.

In most cases, autoimmune hepatitis can be controlled, although ongoing treatment might be required. About 65% of patients will remit within 18 months, while only about 10% of patients will fail treatment altogether – and those patients typically have other contributing factors, such as excessive alcohol use, concurrent viral infection such as hepatitis B or C, or an overlap syndrome.

Another 10% of patients won’t tolerate treatment.

Among those who require treatment indefinitely because of relapse, maintenance therapy with 7.5 mg/day of prednisone and 2 mg per kg/day of azathioprine can be effective for maintaining control. In one study, 85% of patients who relapsed were managed effectively with this strategy at a mean follow-up of 149 months, Dr. Luxon noted.

These patients generally have survival similar to age- and gender-matched controls, so although they have to stay on these low doses of treatment for life, the treatment is quite effective.

In those who fail therapy, it might be useful to increase prednisone to 60 mg/day and azathioprine to 150 mg/day. If there is still no response, it is worth trying mycophenolate mofetil or a calcineurin inhibitor such as tacrolimus, although these have only been assessed in small pilot studies and haven’t proved very successful. Transplant is also an option that generally works well for autoimmune hepatitis in patients who don’t respond to medical therapy and can be considered, particularly in young patients with otherwise good health, Dr. Luxon said.

Dr. Luxon had no relevant disclosures to report.

CHICAGO – A diagnosis of autoimmune hepatitis does not necessarily mandate therapy.

Rather, a decision about therapy should be based on the natural history of the disease, Dr. Bruce Luxon said at a symposium sponsored by the American College of Rheumatology.

Patients for whom treatment is mandatory are those with aspartate aminotransferase (AST) levels greater than 10 times the upper limit of normal, or 5 times the upper limit of normal plus gamma globulin levels greater than twice the upper limit of normal. Data from the 1970s showed that patients with these disease characteristics had a 6-month mortality of 60%, said Dr. Luxon, professor and chair of the department of internal medicine at Georgetown University, Washington.

Similarly, treatment is needed when a biopsy shows "bridging" – or multilobular – necrosis, as studies have shown that progression to cirrhosis occurs in more than 80% of such patients, and 5-year mortality is about 45%.

"In contrast, there is a group of patients whose AST and [alanine transaminase (ALT)] were quite normal or very close to normal [less than twice the normal value]. Those people had a 10-year life expectancy greater than 80%," he said, noting that these patients generally don’t require treatment.

Cirrhotic patients with significant inflammation, on the other hand, might benefit from a 3-6 month trial of therapy to slow down progression, he said adding: "That’s really a decision for a hepatologist to make."

In those who will be treated, prednisone remains the mainstay of therapy, as it has for 50 years, he noted.

It is given initially at a high dose of 60 mg for the first week (or 30 mg plus 50 mg of azathioprine, which is usually given to allow lowering of the prednisone dose). Prednisone is lowered to 40 mg for week 2 (or 20 mg and 50 mg of prednisone and azathioprine, respectively), and to 30 mg for weeks 3 and 4 (or 15 mg and 50 mg of prednisone and azathioprine, respectively).

After week 4, the dose remains 20 mg (or 10 mg and 50 mg of prednisone and azathioprine, respectively) until the clinical end point is reached.

Use of the combination therapy is associated with a much lower occurrence of corticosteroid-related side effects (10% vs. 44%), but not all patients can tolerate the azathioprine. It is fine to give prednisone monotherapy in such patients, he said.

The typical side effects of steroid therapy can occur, including weight gain, unwanted hair growth, acne, and – importantly – bone disease.

"You really want to make sure they are on calcium and vitamin D," he said, noting bisphosphonates, rather than controversial estrogen replacement, are usually prescribed as well.

Azathioprine side effects can include gastrointestinal upset, drug-induced hepatitis in rare cases, and cancer in very rare cases.

The efficacy of treatment should be evaluated on a biochemical or histological basis. But keep in mind that while a failure to normalize liver enzymes suggests residual disease, about half of those who do have normalization will still go on to have significant liver fibrosis and inflammation on biopsy. "So it’s not sufficient to just normalize transaminases," he said.

Since biopsy improvement lags behind biochemical improvement by about 6 months, a repeat biopsy at that time is warranted.

These serial biopsies, which are important in this disease, can also predict whether a patient can be taken off therapy, he said.

Patients with a normal liver biopsy at follow-up will have only about a 15%-20% risk of relapse, so it is reasonable to take them off treatment, he noted.

Conversely, those with interface hepatitis and inflammation on follow-up biopsy will relapse about 90% of the time and require ongoing treatment.

In most cases, autoimmune hepatitis can be controlled, although ongoing treatment might be required. About 65% of patients will remit within 18 months, while only about 10% of patients will fail treatment altogether – and those patients typically have other contributing factors, such as excessive alcohol use, concurrent viral infection such as hepatitis B or C, or an overlap syndrome.

Another 10% of patients won’t tolerate treatment.

Among those who require treatment indefinitely because of relapse, maintenance therapy with 7.5 mg/day of prednisone and 2 mg per kg/day of azathioprine can be effective for maintaining control. In one study, 85% of patients who relapsed were managed effectively with this strategy at a mean follow-up of 149 months, Dr. Luxon noted.

These patients generally have survival similar to age- and gender-matched controls, so although they have to stay on these low doses of treatment for life, the treatment is quite effective.

In those who fail therapy, it might be useful to increase prednisone to 60 mg/day and azathioprine to 150 mg/day. If there is still no response, it is worth trying mycophenolate mofetil or a calcineurin inhibitor such as tacrolimus, although these have only been assessed in small pilot studies and haven’t proved very successful. Transplant is also an option that generally works well for autoimmune hepatitis in patients who don’t respond to medical therapy and can be considered, particularly in young patients with otherwise good health, Dr. Luxon said.

Dr. Luxon had no relevant disclosures to report.

CHICAGO – The risk of both interstitial and obstructive lung disease is increased in patients with rheumatoid arthritis, as is mortality in affected, compared with unaffected, arthritis patients.

In a cohort of rheumatoid arthritis (RA) patients from a single county in Minnesota who have been followed since 1955, the risk of developing interstitial lung disease is about 8%, compared with less than 1% in the general population, Dr. Eric Matteson reported at a symposium sponsored by the American College of Rheumatology.

"The hazard ratio for developing interstitial lung disease, compared to non-RA patients, is about a ninefold increase, so this is an enormous difference," said Dr. Matteson, professor of medicine and chair of the division of rheumatology and health sciences research at the Mayo Clinic, Rochester, Minn.

Furthermore, these patients with interstitial lung disease have much higher mortality than RA patients who do not have interstitial lung disease (hazard ratio 2.14), he said.

The findings compare well with those from a recently completed survey, which used National Center for Health Statistics data and suggested that, while mortality in RA in general has declined, the rates of interstitial lung disease are increasing.

"We’re probably seeing more [interstitial lung disease in RA patients] today than we did maybe 10, 20, and certainly 30 years ago," Dr. Matteson said.

It is possible that the declines in RA mortality overall are outpacing those from interstitial lung disease. Although biologics being used to treat RA are helping joint disease and other extra-articular manifestations of RA, there is no evidence that they influence the development of interstitial lung disease, he suggested.

Obstructive lung disease is also a concern in RA patients, and although the difference in incidence between RA patients and the general population is smaller than with interstitial lung disease, this finding may be more surprising, Dr. Matteson said, noting that this information from the Minnesota cohort was new to him.

"It appears that rheumatoid arthritis is a risk factor for obstructive lung disease," he said. After correcting for age, sex, and smoking status, there is about a 50% increase in the incidence of obstructive lung disease in RA patients, compared with the general population.

The reason for this is unclear, but "intriguing new data" suggest that the cystic fibrosis genes and some related genes are risk factors for developing bronchiolitis and other forms of obstructive disease in RA, so that may be part of the biologic answer, he said.

There is a biologic reason why these patients also may be at higher risk for obstructive lung disease as well as interstitial lung disease, he said.

And like interstitial lung disease, obstructive lung disease also adversely affects mortality in RA patients (hazard ratio of 1.87 for affected vs. nonaffected RA patients), he noted.

CHICAGO – The risk of both interstitial and obstructive lung disease is increased in patients with rheumatoid arthritis, as is mortality in affected, compared with unaffected, arthritis patients.

In a cohort of rheumatoid arthritis (RA) patients from a single county in Minnesota who have been followed since 1955, the risk of developing interstitial lung disease is about 8%, compared with less than 1% in the general population, Dr. Eric Matteson reported at a symposium sponsored by the American College of Rheumatology.

"The hazard ratio for developing interstitial lung disease, compared to non-RA patients, is about a ninefold increase, so this is an enormous difference," said Dr. Matteson, professor of medicine and chair of the division of rheumatology and health sciences research at the Mayo Clinic, Rochester, Minn.

Furthermore, these patients with interstitial lung disease have much higher mortality than RA patients who do not have interstitial lung disease (hazard ratio 2.14), he said.

The findings compare well with those from a recently completed survey, which used National Center for Health Statistics data and suggested that, while mortality in RA in general has declined, the rates of interstitial lung disease are increasing.

"We’re probably seeing more [interstitial lung disease in RA patients] today than we did maybe 10, 20, and certainly 30 years ago," Dr. Matteson said.

It is possible that the declines in RA mortality overall are outpacing those from interstitial lung disease. Although biologics being used to treat RA are helping joint disease and other extra-articular manifestations of RA, there is no evidence that they influence the development of interstitial lung disease, he suggested.

Obstructive lung disease is also a concern in RA patients, and although the difference in incidence between RA patients and the general population is smaller than with interstitial lung disease, this finding may be more surprising, Dr. Matteson said, noting that this information from the Minnesota cohort was new to him.

"It appears that rheumatoid arthritis is a risk factor for obstructive lung disease," he said. After correcting for age, sex, and smoking status, there is about a 50% increase in the incidence of obstructive lung disease in RA patients, compared with the general population.

The reason for this is unclear, but "intriguing new data" suggest that the cystic fibrosis genes and some related genes are risk factors for developing bronchiolitis and other forms of obstructive disease in RA, so that may be part of the biologic answer, he said.

There is a biologic reason why these patients also may be at higher risk for obstructive lung disease as well as interstitial lung disease, he said.

And like interstitial lung disease, obstructive lung disease also adversely affects mortality in RA patients (hazard ratio of 1.87 for affected vs. nonaffected RA patients), he noted.

CHICAGO – The risk of both interstitial and obstructive lung disease is increased in patients with rheumatoid arthritis, as is mortality in affected, compared with unaffected, arthritis patients.

In a cohort of rheumatoid arthritis (RA) patients from a single county in Minnesota who have been followed since 1955, the risk of developing interstitial lung disease is about 8%, compared with less than 1% in the general population, Dr. Eric Matteson reported at a symposium sponsored by the American College of Rheumatology.

"The hazard ratio for developing interstitial lung disease, compared to non-RA patients, is about a ninefold increase, so this is an enormous difference," said Dr. Matteson, professor of medicine and chair of the division of rheumatology and health sciences research at the Mayo Clinic, Rochester, Minn.

Furthermore, these patients with interstitial lung disease have much higher mortality than RA patients who do not have interstitial lung disease (hazard ratio 2.14), he said.

The findings compare well with those from a recently completed survey, which used National Center for Health Statistics data and suggested that, while mortality in RA in general has declined, the rates of interstitial lung disease are increasing.

"We’re probably seeing more [interstitial lung disease in RA patients] today than we did maybe 10, 20, and certainly 30 years ago," Dr. Matteson said.

It is possible that the declines in RA mortality overall are outpacing those from interstitial lung disease. Although biologics being used to treat RA are helping joint disease and other extra-articular manifestations of RA, there is no evidence that they influence the development of interstitial lung disease, he suggested.

Obstructive lung disease is also a concern in RA patients, and although the difference in incidence between RA patients and the general population is smaller than with interstitial lung disease, this finding may be more surprising, Dr. Matteson said, noting that this information from the Minnesota cohort was new to him.

"It appears that rheumatoid arthritis is a risk factor for obstructive lung disease," he said. After correcting for age, sex, and smoking status, there is about a 50% increase in the incidence of obstructive lung disease in RA patients, compared with the general population.

The reason for this is unclear, but "intriguing new data" suggest that the cystic fibrosis genes and some related genes are risk factors for developing bronchiolitis and other forms of obstructive disease in RA, so that may be part of the biologic answer, he said.

There is a biologic reason why these patients also may be at higher risk for obstructive lung disease as well as interstitial lung disease, he said.

And like interstitial lung disease, obstructive lung disease also adversely affects mortality in RA patients (hazard ratio of 1.87 for affected vs. nonaffected RA patients), he noted.

CHICAGO – The risk of both interstitial and obstructive lung disease is increased in patients with rheumatoid arthritis, as is mortality in affected, compared with unaffected, arthritis patients.

In a cohort of rheumatoid arthritis (RA) patients from a single county in Minnesota who have been followed since 1955, the risk of developing interstitial lung disease is about 8%, compared with less than 1% in the general population, Dr. Eric Matteson reported at a symposium sponsored by the American College of Rheumatology.

"The hazard ratio for developing interstitial lung disease, compared to non-RA patients, is about a ninefold increase, so this is an enormous difference," said Dr. Matteson, professor of medicine and chair of the division of rheumatology and health sciences research at the Mayo Clinic, Rochester, Minn.

Furthermore, these patients with interstitial lung disease have much higher mortality than RA patients who do not have interstitial lung disease (hazard ratio 2.14), he said.

The findings compare well with those from a recently completed survey, which used National Center for Health Statistics data and suggested that, while mortality in RA in general has declined, the rates of interstitial lung disease are increasing.

"We’re probably seeing more [interstitial lung disease in RA patients] today than we did maybe 10, 20, and certainly 30 years ago," Dr. Matteson said.

It is possible that the declines in RA mortality overall are outpacing those from interstitial lung disease. Although biologics being used to treat RA are helping joint disease and other extra-articular manifestations of RA, there is no evidence that they influence the development of interstitial lung disease, he suggested.

Obstructive lung disease is also a concern in RA patients, and although the difference in incidence between RA patients and the general population is smaller than with interstitial lung disease, this finding may be more surprising, Dr. Matteson said, noting that this information from the Minnesota cohort was new to him.

"It appears that rheumatoid arthritis is a risk factor for obstructive lung disease," he said. After correcting for age, sex, and smoking status, there is about a 50% increase in the incidence of obstructive lung disease in RA patients, compared with the general population.

The reason for this is unclear, but "intriguing new data" suggest that the cystic fibrosis genes and some related genes are risk factors for developing bronchiolitis and other forms of obstructive disease in RA, so that may be part of the biologic answer, he said.

There is a biologic reason why these patients also may be at higher risk for obstructive lung disease as well as interstitial lung disease, he said.

And like interstitial lung disease, obstructive lung disease also adversely affects mortality in RA patients (hazard ratio of 1.87 for affected vs. nonaffected RA patients), he noted.

CHICAGO – The risk of both interstitial and obstructive lung disease is increased in patients with rheumatoid arthritis, as is mortality in affected, compared with unaffected, arthritis patients.

In a cohort of rheumatoid arthritis (RA) patients from a single county in Minnesota who have been followed since 1955, the risk of developing interstitial lung disease is about 8%, compared with less than 1% in the general population, Dr. Eric Matteson reported at a symposium sponsored by the American College of Rheumatology.

"The hazard ratio for developing interstitial lung disease, compared to non-RA patients, is about a ninefold increase, so this is an enormous difference," said Dr. Matteson, professor of medicine and chair of the division of rheumatology and health sciences research at the Mayo Clinic, Rochester, Minn.

Furthermore, these patients with interstitial lung disease have much higher mortality than RA patients who do not have interstitial lung disease (hazard ratio 2.14), he said.

The findings compare well with those from a recently completed survey, which used National Center for Health Statistics data and suggested that, while mortality in RA in general has declined, the rates of interstitial lung disease are increasing.

"We’re probably seeing more [interstitial lung disease in RA patients] today than we did maybe 10, 20, and certainly 30 years ago," Dr. Matteson said.

It is possible that the declines in RA mortality overall are outpacing those from interstitial lung disease. Although biologics being used to treat RA are helping joint disease and other extra-articular manifestations of RA, there is no evidence that they influence the development of interstitial lung disease, he suggested.

Obstructive lung disease is also a concern in RA patients, and although the difference in incidence between RA patients and the general population is smaller than with interstitial lung disease, this finding may be more surprising, Dr. Matteson said, noting that this information from the Minnesota cohort was new to him.

"It appears that rheumatoid arthritis is a risk factor for obstructive lung disease," he said. After correcting for age, sex, and smoking status, there is about a 50% increase in the incidence of obstructive lung disease in RA patients, compared with the general population.

The reason for this is unclear, but "intriguing new data" suggest that the cystic fibrosis genes and some related genes are risk factors for developing bronchiolitis and other forms of obstructive disease in RA, so that may be part of the biologic answer, he said.

There is a biologic reason why these patients also may be at higher risk for obstructive lung disease as well as interstitial lung disease, he said.

And like interstitial lung disease, obstructive lung disease also adversely affects mortality in RA patients (hazard ratio of 1.87 for affected vs. nonaffected RA patients), he noted.

CHICAGO – The risk of both interstitial and obstructive lung disease is increased in patients with rheumatoid arthritis, as is mortality in affected, compared with unaffected, arthritis patients.

In a cohort of rheumatoid arthritis (RA) patients from a single county in Minnesota who have been followed since 1955, the risk of developing interstitial lung disease is about 8%, compared with less than 1% in the general population, Dr. Eric Matteson reported at a symposium sponsored by the American College of Rheumatology.

"The hazard ratio for developing interstitial lung disease, compared to non-RA patients, is about a ninefold increase, so this is an enormous difference," said Dr. Matteson, professor of medicine and chair of the division of rheumatology and health sciences research at the Mayo Clinic, Rochester, Minn.

Furthermore, these patients with interstitial lung disease have much higher mortality than RA patients who do not have interstitial lung disease (hazard ratio 2.14), he said.

The findings compare well with those from a recently completed survey, which used National Center for Health Statistics data and suggested that, while mortality in RA in general has declined, the rates of interstitial lung disease are increasing.

"We’re probably seeing more [interstitial lung disease in RA patients] today than we did maybe 10, 20, and certainly 30 years ago," Dr. Matteson said.

It is possible that the declines in RA mortality overall are outpacing those from interstitial lung disease. Although biologics being used to treat RA are helping joint disease and other extra-articular manifestations of RA, there is no evidence that they influence the development of interstitial lung disease, he suggested.

Obstructive lung disease is also a concern in RA patients, and although the difference in incidence between RA patients and the general population is smaller than with interstitial lung disease, this finding may be more surprising, Dr. Matteson said, noting that this information from the Minnesota cohort was new to him.

"It appears that rheumatoid arthritis is a risk factor for obstructive lung disease," he said. After correcting for age, sex, and smoking status, there is about a 50% increase in the incidence of obstructive lung disease in RA patients, compared with the general population.

The reason for this is unclear, but "intriguing new data" suggest that the cystic fibrosis genes and some related genes are risk factors for developing bronchiolitis and other forms of obstructive disease in RA, so that may be part of the biologic answer, he said.

There is a biologic reason why these patients also may be at higher risk for obstructive lung disease as well as interstitial lung disease, he said.

And like interstitial lung disease, obstructive lung disease also adversely affects mortality in RA patients (hazard ratio of 1.87 for affected vs. nonaffected RA patients), he noted.

CHICAGO – Despite dramatic clinical benefit, the standard treatments for ankylosing spondylitis do not appear to alter the natural history of the disease.

"We’d like to believe we’re actually doing something substantial for our patients in addition to actually relieving symptoms," said Dr. Michael H. Weisman, adding that this is an area of "hot, current controversy."

Nonsteroidal anti-inflammatory drugs, for example, are clinically very useful for treating patients with ankylosing spondylitis (AS). In a study of NSAID treatment for AS and mechanical back pain, good clinical response occurred in 75% of the AS patients, compared with only about 15% of the patients with mechanical back pain (Rev. Rhum. Engl. Ed. 1995;62:10-5), Dr. Weisman said at a symposium sponsored by the American College of Rheumatology.

The response of AS patients to NSAIDs is so good, in fact, that it can be helpful for confirming the diagnosis. A greater complete response may indicate that AS is the cause of symptoms, he said.

Another study demonstrated that 70% of AS patients who received etoricoxib had a good clinical response, compared with about 20% who received placebo (Arthritis Rheum. 2005;52:1205-15).

However, the effects of NSAIDs on radiographic progression of disease are questionable, at best, said Dr. Weisman, director of the division of rheumatology and professor of medicine at Cedars-Sinai Medical Center, Los Angeles.

Although findings from one study showed that there was less radiographic progression of disease after 2 years in patients on continuous versus on-demand NSAIDs, with a mean change on the modified Stoke Ankylosing Spondylitis Spinal Score of 0.4 vs. 1.5, respectively (Arthritis Rheum. 2005;52:1756-65), most experts "take this particular study with a grain of salt," Dr. Weisman said.

That’s in part because the mean difference in dose between the continuous and on-demand patients was only 50 mg/day. It’s very difficult to believe that a difference of 50 mg in celecoxib could make a difference in actually reducing the amount of bone formation in AS, he said.

Tumor necrosis factor (TNF) blockers also provide excellent clinical benefit and are approved for use in AS. Patients experience tremendous response, perhaps to even a greater degree than do rheumatoid arthritis patients and, unlike RA patients, there appears to be no increased risk of serious infection with treatment, he noted.

In a recent meta-analysis of randomized, placebo-controlled studies of anti-TNF drugs in AS, no difference was seen in the rate of serious infections in those who received active treatment versus those who received placebo (Ann. Rheum. Dis. 2010; 69:1756-61).

However, while anti-TNF agents have the potential to alter the natural history and prognosis of AS, there is also no evidence in any studies of etanercept, infliximab, or adalimumab that treatment over 2 years inhibits radiographic progression of disease.

This is a source of frustration, Dr. Weisman said.

Disease progression in AS is generally very slow. Only about 25% of patients experience disease progression. Inflammation appears to play a role, with syndesmophytes developing significantly more frequently in vertebral corners in patients with inflammation versus those without inflammation (20% vs. 5% of patients in one study). Paradoxically, though, syndesmophytes develop more frequently in vertebral corners where inflammation has resolved than in those where it persisted after anti-TNF therapy, Dr. Weisman said.

This raises concerns about whether the control of inflammation using anti-TNF agents actually liberates bone formation in these patients, he noted.

In addition to the inflammation/syndesmophyte associations, syndesmophytes sometimes form in patients with normal x-rays or MRIs, he said.

"We really don’t know why syndesmophytes form in this disease," he added, noting that, while there has been some understanding of the fact that AS biology differs from RA biology (AS is a bone-forming disease, for example), new understanding of the biology is beginning to emerge. Perhaps this new understanding, along with the discovery of bone-related genes, will help define subsets of individual pathways that can be targeted, he suggested.

Dr. Weisman had no disclosures to report.

CHICAGO – Despite dramatic clinical benefit, the standard treatments for ankylosing spondylitis do not appear to alter the natural history of the disease.

"We’d like to believe we’re actually doing something substantial for our patients in addition to actually relieving symptoms," said Dr. Michael H. Weisman, adding that this is an area of "hot, current controversy."

Nonsteroidal anti-inflammatory drugs, for example, are clinically very useful for treating patients with ankylosing spondylitis (AS). In a study of NSAID treatment for AS and mechanical back pain, good clinical response occurred in 75% of the AS patients, compared with only about 15% of the patients with mechanical back pain (Rev. Rhum. Engl. Ed. 1995;62:10-5), Dr. Weisman said at a symposium sponsored by the American College of Rheumatology.

The response of AS patients to NSAIDs is so good, in fact, that it can be helpful for confirming the diagnosis. A greater complete response may indicate that AS is the cause of symptoms, he said.

Another study demonstrated that 70% of AS patients who received etoricoxib had a good clinical response, compared with about 20% who received placebo (Arthritis Rheum. 2005;52:1205-15).

However, the effects of NSAIDs on radiographic progression of disease are questionable, at best, said Dr. Weisman, director of the division of rheumatology and professor of medicine at Cedars-Sinai Medical Center, Los Angeles.

Although findings from one study showed that there was less radiographic progression of disease after 2 years in patients on continuous versus on-demand NSAIDs, with a mean change on the modified Stoke Ankylosing Spondylitis Spinal Score of 0.4 vs. 1.5, respectively (Arthritis Rheum. 2005;52:1756-65), most experts "take this particular study with a grain of salt," Dr. Weisman said.

That’s in part because the mean difference in dose between the continuous and on-demand patients was only 50 mg/day. It’s very difficult to believe that a difference of 50 mg in celecoxib could make a difference in actually reducing the amount of bone formation in AS, he said.

Tumor necrosis factor (TNF) blockers also provide excellent clinical benefit and are approved for use in AS. Patients experience tremendous response, perhaps to even a greater degree than do rheumatoid arthritis patients and, unlike RA patients, there appears to be no increased risk of serious infection with treatment, he noted.

In a recent meta-analysis of randomized, placebo-controlled studies of anti-TNF drugs in AS, no difference was seen in the rate of serious infections in those who received active treatment versus those who received placebo (Ann. Rheum. Dis. 2010; 69:1756-61).

However, while anti-TNF agents have the potential to alter the natural history and prognosis of AS, there is also no evidence in any studies of etanercept, infliximab, or adalimumab that treatment over 2 years inhibits radiographic progression of disease.

This is a source of frustration, Dr. Weisman said.

Disease progression in AS is generally very slow. Only about 25% of patients experience disease progression. Inflammation appears to play a role, with syndesmophytes developing significantly more frequently in vertebral corners in patients with inflammation versus those without inflammation (20% vs. 5% of patients in one study). Paradoxically, though, syndesmophytes develop more frequently in vertebral corners where inflammation has resolved than in those where it persisted after anti-TNF therapy, Dr. Weisman said.

This raises concerns about whether the control of inflammation using anti-TNF agents actually liberates bone formation in these patients, he noted.

In addition to the inflammation/syndesmophyte associations, syndesmophytes sometimes form in patients with normal x-rays or MRIs, he said.

"We really don’t know why syndesmophytes form in this disease," he added, noting that, while there has been some understanding of the fact that AS biology differs from RA biology (AS is a bone-forming disease, for example), new understanding of the biology is beginning to emerge. Perhaps this new understanding, along with the discovery of bone-related genes, will help define subsets of individual pathways that can be targeted, he suggested.

Dr. Weisman had no disclosures to report.

CHICAGO – Despite dramatic clinical benefit, the standard treatments for ankylosing spondylitis do not appear to alter the natural history of the disease.

"We’d like to believe we’re actually doing something substantial for our patients in addition to actually relieving symptoms," said Dr. Michael H. Weisman, adding that this is an area of "hot, current controversy."

Nonsteroidal anti-inflammatory drugs, for example, are clinically very useful for treating patients with ankylosing spondylitis (AS). In a study of NSAID treatment for AS and mechanical back pain, good clinical response occurred in 75% of the AS patients, compared with only about 15% of the patients with mechanical back pain (Rev. Rhum. Engl. Ed. 1995;62:10-5), Dr. Weisman said at a symposium sponsored by the American College of Rheumatology.

The response of AS patients to NSAIDs is so good, in fact, that it can be helpful for confirming the diagnosis. A greater complete response may indicate that AS is the cause of symptoms, he said.

Another study demonstrated that 70% of AS patients who received etoricoxib had a good clinical response, compared with about 20% who received placebo (Arthritis Rheum. 2005;52:1205-15).

However, the effects of NSAIDs on radiographic progression of disease are questionable, at best, said Dr. Weisman, director of the division of rheumatology and professor of medicine at Cedars-Sinai Medical Center, Los Angeles.

Although findings from one study showed that there was less radiographic progression of disease after 2 years in patients on continuous versus on-demand NSAIDs, with a mean change on the modified Stoke Ankylosing Spondylitis Spinal Score of 0.4 vs. 1.5, respectively (Arthritis Rheum. 2005;52:1756-65), most experts "take this particular study with a grain of salt," Dr. Weisman said.

That’s in part because the mean difference in dose between the continuous and on-demand patients was only 50 mg/day. It’s very difficult to believe that a difference of 50 mg in celecoxib could make a difference in actually reducing the amount of bone formation in AS, he said.

Tumor necrosis factor (TNF) blockers also provide excellent clinical benefit and are approved for use in AS. Patients experience tremendous response, perhaps to even a greater degree than do rheumatoid arthritis patients and, unlike RA patients, there appears to be no increased risk of serious infection with treatment, he noted.

In a recent meta-analysis of randomized, placebo-controlled studies of anti-TNF drugs in AS, no difference was seen in the rate of serious infections in those who received active treatment versus those who received placebo (Ann. Rheum. Dis. 2010; 69:1756-61).

However, while anti-TNF agents have the potential to alter the natural history and prognosis of AS, there is also no evidence in any studies of etanercept, infliximab, or adalimumab that treatment over 2 years inhibits radiographic progression of disease.

This is a source of frustration, Dr. Weisman said.

Disease progression in AS is generally very slow. Only about 25% of patients experience disease progression. Inflammation appears to play a role, with syndesmophytes developing significantly more frequently in vertebral corners in patients with inflammation versus those without inflammation (20% vs. 5% of patients in one study). Paradoxically, though, syndesmophytes develop more frequently in vertebral corners where inflammation has resolved than in those where it persisted after anti-TNF therapy, Dr. Weisman said.

This raises concerns about whether the control of inflammation using anti-TNF agents actually liberates bone formation in these patients, he noted.

In addition to the inflammation/syndesmophyte associations, syndesmophytes sometimes form in patients with normal x-rays or MRIs, he said.

"We really don’t know why syndesmophytes form in this disease," he added, noting that, while there has been some understanding of the fact that AS biology differs from RA biology (AS is a bone-forming disease, for example), new understanding of the biology is beginning to emerge. Perhaps this new understanding, along with the discovery of bone-related genes, will help define subsets of individual pathways that can be targeted, he suggested.

Dr. Weisman had no disclosures to report.

CHICAGO – Despite dramatic clinical benefit, the standard treatments for ankylosing spondylitis do not appear to alter the natural history of the disease.

"We’d like to believe we’re actually doing something substantial for our patients in addition to actually relieving symptoms," said Dr. Michael H. Weisman, adding that this is an area of "hot, current controversy."

Nonsteroidal anti-inflammatory drugs, for example, are clinically very useful for treating patients with ankylosing spondylitis (AS). In a study of NSAID treatment for AS and mechanical back pain, good clinical response occurred in 75% of the AS patients, compared with only about 15% of the patients with mechanical back pain (Rev. Rhum. Engl. Ed. 1995;62:10-5), Dr. Weisman said at a symposium sponsored by the American College of Rheumatology.

The response of AS patients to NSAIDs is so good, in fact, that it can be helpful for confirming the diagnosis. A greater complete response may indicate that AS is the cause of symptoms, he said.

Another study demonstrated that 70% of AS patients who received etoricoxib had a good clinical response, compared with about 20% who received placebo (Arthritis Rheum. 2005;52:1205-15).

However, the effects of NSAIDs on radiographic progression of disease are questionable, at best, said Dr. Weisman, director of the division of rheumatology and professor of medicine at Cedars-Sinai Medical Center, Los Angeles.

Although findings from one study showed that there was less radiographic progression of disease after 2 years in patients on continuous versus on-demand NSAIDs, with a mean change on the modified Stoke Ankylosing Spondylitis Spinal Score of 0.4 vs. 1.5, respectively (Arthritis Rheum. 2005;52:1756-65), most experts "take this particular study with a grain of salt," Dr. Weisman said.

That’s in part because the mean difference in dose between the continuous and on-demand patients was only 50 mg/day. It’s very difficult to believe that a difference of 50 mg in celecoxib could make a difference in actually reducing the amount of bone formation in AS, he said.

Tumor necrosis factor (TNF) blockers also provide excellent clinical benefit and are approved for use in AS. Patients experience tremendous response, perhaps to even a greater degree than do rheumatoid arthritis patients and, unlike RA patients, there appears to be no increased risk of serious infection with treatment, he noted.

In a recent meta-analysis of randomized, placebo-controlled studies of anti-TNF drugs in AS, no difference was seen in the rate of serious infections in those who received active treatment versus those who received placebo (Ann. Rheum. Dis. 2010; 69:1756-61).

However, while anti-TNF agents have the potential to alter the natural history and prognosis of AS, there is also no evidence in any studies of etanercept, infliximab, or adalimumab that treatment over 2 years inhibits radiographic progression of disease.

This is a source of frustration, Dr. Weisman said.

Disease progression in AS is generally very slow. Only about 25% of patients experience disease progression. Inflammation appears to play a role, with syndesmophytes developing significantly more frequently in vertebral corners in patients with inflammation versus those without inflammation (20% vs. 5% of patients in one study). Paradoxically, though, syndesmophytes develop more frequently in vertebral corners where inflammation has resolved than in those where it persisted after anti-TNF therapy, Dr. Weisman said.

This raises concerns about whether the control of inflammation using anti-TNF agents actually liberates bone formation in these patients, he noted.

In addition to the inflammation/syndesmophyte associations, syndesmophytes sometimes form in patients with normal x-rays or MRIs, he said.

"We really don’t know why syndesmophytes form in this disease," he added, noting that, while there has been some understanding of the fact that AS biology differs from RA biology (AS is a bone-forming disease, for example), new understanding of the biology is beginning to emerge. Perhaps this new understanding, along with the discovery of bone-related genes, will help define subsets of individual pathways that can be targeted, he suggested.

Dr. Weisman had no disclosures to report.

CHICAGO – Despite dramatic clinical benefit, the standard treatments for ankylosing spondylitis do not appear to alter the natural history of the disease.

"We’d like to believe we’re actually doing something substantial for our patients in addition to actually relieving symptoms," said Dr. Michael H. Weisman, adding that this is an area of "hot, current controversy."

Nonsteroidal anti-inflammatory drugs, for example, are clinically very useful for treating patients with ankylosing spondylitis (AS). In a study of NSAID treatment for AS and mechanical back pain, good clinical response occurred in 75% of the AS patients, compared with only about 15% of the patients with mechanical back pain (Rev. Rhum. Engl. Ed. 1995;62:10-5), Dr. Weisman said at a symposium sponsored by the American College of Rheumatology.

The response of AS patients to NSAIDs is so good, in fact, that it can be helpful for confirming the diagnosis. A greater complete response may indicate that AS is the cause of symptoms, he said.

Another study demonstrated that 70% of AS patients who received etoricoxib had a good clinical response, compared with about 20% who received placebo (Arthritis Rheum. 2005;52:1205-15).

However, the effects of NSAIDs on radiographic progression of disease are questionable, at best, said Dr. Weisman, director of the division of rheumatology and professor of medicine at Cedars-Sinai Medical Center, Los Angeles.

Although findings from one study showed that there was less radiographic progression of disease after 2 years in patients on continuous versus on-demand NSAIDs, with a mean change on the modified Stoke Ankylosing Spondylitis Spinal Score of 0.4 vs. 1.5, respectively (Arthritis Rheum. 2005;52:1756-65), most experts "take this particular study with a grain of salt," Dr. Weisman said.

That’s in part because the mean difference in dose between the continuous and on-demand patients was only 50 mg/day. It’s very difficult to believe that a difference of 50 mg in celecoxib could make a difference in actually reducing the amount of bone formation in AS, he said.

Tumor necrosis factor (TNF) blockers also provide excellent clinical benefit and are approved for use in AS. Patients experience tremendous response, perhaps to even a greater degree than do rheumatoid arthritis patients and, unlike RA patients, there appears to be no increased risk of serious infection with treatment, he noted.

In a recent meta-analysis of randomized, placebo-controlled studies of anti-TNF drugs in AS, no difference was seen in the rate of serious infections in those who received active treatment versus those who received placebo (Ann. Rheum. Dis. 2010; 69:1756-61).

However, while anti-TNF agents have the potential to alter the natural history and prognosis of AS, there is also no evidence in any studies of etanercept, infliximab, or adalimumab that treatment over 2 years inhibits radiographic progression of disease.

This is a source of frustration, Dr. Weisman said.

Disease progression in AS is generally very slow. Only about 25% of patients experience disease progression. Inflammation appears to play a role, with syndesmophytes developing significantly more frequently in vertebral corners in patients with inflammation versus those without inflammation (20% vs. 5% of patients in one study). Paradoxically, though, syndesmophytes develop more frequently in vertebral corners where inflammation has resolved than in those where it persisted after anti-TNF therapy, Dr. Weisman said.

This raises concerns about whether the control of inflammation using anti-TNF agents actually liberates bone formation in these patients, he noted.

In addition to the inflammation/syndesmophyte associations, syndesmophytes sometimes form in patients with normal x-rays or MRIs, he said.

"We really don’t know why syndesmophytes form in this disease," he added, noting that, while there has been some understanding of the fact that AS biology differs from RA biology (AS is a bone-forming disease, for example), new understanding of the biology is beginning to emerge. Perhaps this new understanding, along with the discovery of bone-related genes, will help define subsets of individual pathways that can be targeted, he suggested.

Dr. Weisman had no disclosures to report.

CHICAGO – Despite dramatic clinical benefit, the standard treatments for ankylosing spondylitis do not appear to alter the natural history of the disease.

"We’d like to believe we’re actually doing something substantial for our patients in addition to actually relieving symptoms," said Dr. Michael H. Weisman, adding that this is an area of "hot, current controversy."

Nonsteroidal anti-inflammatory drugs, for example, are clinically very useful for treating patients with ankylosing spondylitis (AS). In a study of NSAID treatment for AS and mechanical back pain, good clinical response occurred in 75% of the AS patients, compared with only about 15% of the patients with mechanical back pain (Rev. Rhum. Engl. Ed. 1995;62:10-5), Dr. Weisman said at a symposium sponsored by the American College of Rheumatology.

The response of AS patients to NSAIDs is so good, in fact, that it can be helpful for confirming the diagnosis. A greater complete response may indicate that AS is the cause of symptoms, he said.

Another study demonstrated that 70% of AS patients who received etoricoxib had a good clinical response, compared with about 20% who received placebo (Arthritis Rheum. 2005;52:1205-15).

However, the effects of NSAIDs on radiographic progression of disease are questionable, at best, said Dr. Weisman, director of the division of rheumatology and professor of medicine at Cedars-Sinai Medical Center, Los Angeles.

Although findings from one study showed that there was less radiographic progression of disease after 2 years in patients on continuous versus on-demand NSAIDs, with a mean change on the modified Stoke Ankylosing Spondylitis Spinal Score of 0.4 vs. 1.5, respectively (Arthritis Rheum. 2005;52:1756-65), most experts "take this particular study with a grain of salt," Dr. Weisman said.

That’s in part because the mean difference in dose between the continuous and on-demand patients was only 50 mg/day. It’s very difficult to believe that a difference of 50 mg in celecoxib could make a difference in actually reducing the amount of bone formation in AS, he said.

Tumor necrosis factor (TNF) blockers also provide excellent clinical benefit and are approved for use in AS. Patients experience tremendous response, perhaps to even a greater degree than do rheumatoid arthritis patients and, unlike RA patients, there appears to be no increased risk of serious infection with treatment, he noted.

In a recent meta-analysis of randomized, placebo-controlled studies of anti-TNF drugs in AS, no difference was seen in the rate of serious infections in those who received active treatment versus those who received placebo (Ann. Rheum. Dis. 2010; 69:1756-61).

However, while anti-TNF agents have the potential to alter the natural history and prognosis of AS, there is also no evidence in any studies of etanercept, infliximab, or adalimumab that treatment over 2 years inhibits radiographic progression of disease.

This is a source of frustration, Dr. Weisman said.

Disease progression in AS is generally very slow. Only about 25% of patients experience disease progression. Inflammation appears to play a role, with syndesmophytes developing significantly more frequently in vertebral corners in patients with inflammation versus those without inflammation (20% vs. 5% of patients in one study). Paradoxically, though, syndesmophytes develop more frequently in vertebral corners where inflammation has resolved than in those where it persisted after anti-TNF therapy, Dr. Weisman said.

This raises concerns about whether the control of inflammation using anti-TNF agents actually liberates bone formation in these patients, he noted.

In addition to the inflammation/syndesmophyte associations, syndesmophytes sometimes form in patients with normal x-rays or MRIs, he said.

"We really don’t know why syndesmophytes form in this disease," he added, noting that, while there has been some understanding of the fact that AS biology differs from RA biology (AS is a bone-forming disease, for example), new understanding of the biology is beginning to emerge. Perhaps this new understanding, along with the discovery of bone-related genes, will help define subsets of individual pathways that can be targeted, he suggested.

Dr. Weisman had no disclosures to report.